1. Rosenbloom AL, Ongley JP. Who provides what
services to children in private medical practice?
Am J Dis
Child. 1974;127:357-361.
[PubMed: 4405998]
3. Rosenbloom AL, Deeb LC, Allen L, Pollock BH. Characteristics
of pediatric endocrinology practice: a workforce study. The
Endocrinologist. 1998;8:213-218.
4. American Diabetes Association. Position Statement: Diagnosis
and Classification of Diabetes Mellitus. Report of the Expert Committee
on the Diagnosis and Classification of Diabetes Mellitus. Diabetes
Care. 2005;28:S37-S42.
5. National Diabetes Data Group. Classification and diagnosis
of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28:1039-1057.
6. Winter WE, Maclaren NK, Riley WJ, Clarke DW, Kappy MS, Spillar
RP. Maturity-onset diabetes of youth in black Americans.
N
Engl J Med. 1987;316:285-291.
[PubMed: 3543673]
7. Banerji MA, Chaiken RL, Juey H, et al. GAD antibody negative
NIDDM in adult with black subjects with diabetic ketoacidosis and
increased frequency of human leukocyte antigen DR3 and DR4: Flatbush diabetes.
Diabetes. 1994;43:741-745.
[PubMed: 8194658]
8. American Diabetes Association. Type 2 diabetes in children
and adolescents: consensus conference report. Diabetes Care. 2000;23:381-389.
9. Winter WE. Molecular and biochemical analysis of the MODY
syndromes.
Pediatr Diabetes. 2000;1:88-117.
[PubMed: 15016234]
10. Reardon W, Ross RJM, Sweeney MG, et al. Diabetes mellitus
associated with a pathogenic point mutation in mitochondrial DNA.
Lancet. 1992;340:1376–1379.
[PubMed: 1360090]
11. van den Ouwenland JMW, Lemkes HHPJ, Ruitenbeek W, et al.
Mutation in mitochondrial tRNA (Leu(URR) gene in a large pedigree
with maternally transmitted type II diabetes mellitus and deafness. Nat
Genet. 1992;1:368-371.
12. Kadowaki T, Kadowaki H, Mori Y, et al. A subtype of diabetes
mellitus associated with a mutation of mitochondrial DNA.
N
Engl J Med. 1994;330:962-968.
[PubMed: 8121460]
13. Taylor SI. Lilly Lecture: molecular mechanisms of insulin
resistance: lessons from patients with mutations in the insulin-receptor
gene.
Diabetes. 1992;41:1473-1490.
[PubMed: 1327927]
14. Rosenbloom AL, Goldstein S, Yip CC. Normal insulin binding
to cultured fibroblasts from patients with lipoatrophic diabetes.
J
Clin Endocrinol Metab. 1977;44:803.806.
[PubMed: 849993]
15. Moran A, Doherty L, Wang X, Thomas W. Abnormal
glucose metabolism in cystic fibrosis.
J Pediatr. 1998;133:10-17.
[PubMed: 9672504]
16. Berelowitz M, Eugene HG. Non-insulin-dependent diabetes
mellitus secondary to other endocrine disorders. In: LeRoith D,
Taylor SI, Olefsky JM, eds. Diabetes Mellitus. New
York: Lippincott-Raven; 1996:496-502.
17. WS Cutfield, P Wilton, H Bennmarker, et al. Incidence of
diabetes mellitus and impaired glucose tolerance in children and
adolescents receiving growth hormone treatment. Lancet. 2000;355:610-613.
18. Rosenbloom AL. Hot topic. Fetal growth, adrenocortical function,
and the risk for type 2 diabetes.
Pediatr Diabetes. 2000;1:150-154.
[PubMed: 15016226]
19. Pandit MK, Burke J, Gustafson AB, et al. Drug-induced disorders
of glucose tolerance.
Ann Int Med. 1993;118:529-540.
[PubMed: 8442624]
20. O’Byrne S, Feely J. Effects of drugs on glucose
tolerance in non-insulin-dependent diabetes (parts I and II).
Drugs. 1990;40:203-219.
[PubMed: 2226212]
21. Bouchard P, Sai P, Reach G, Caubarrere I, Ganeval D, Assan
R. Diabetes mellitus following pentamidine-induced hypoglycemia
in humans.
Diabetes. 1982;31:40-45.
[PubMed: 6759211]
22. Assan R, Perronne C, Assan D, et al. Pentamidine-induced
derangements of glucose homeostasis.
Diabetes Care. 1995;18:47-55.
[PubMed: 7698047]
23. Gallanosa AG, Spyker DA, Curnow RT. Diabetes mellitus associated
with autonomic and peripheral neuropathy after Vacor poisoning:
a review.
Clin Toxicol. 1981; 18:441-449.
[PubMed: 6263541]
24. Esposti MD, Ngo A, Myers MA. Inhibition of mitochondrial
complex I may account for IDDM induced by intoxication with rodenticide
Vacor.
Diabetes. 1996;45:1531-1534.
[PubMed: 8866557]
25. Rettenbacher MA. Disturbances of glucose and lipid metabolism
during treatment with new generation antipsychotics.
Curr
Opin Psychiatry. 2005;18:175-179.
[PubMed: 16639171]
26. Davis V, Rosenbloom AL. Metabolic effects of atypical antipsychotics. Pediatr
Diabetes. 2006;7: 176-186.
27. Forrest, JA, Menser MA, Burgess JA. High frequency of diabetes
mellitus in young patients with congenital rubella; Lancet. 1971;ii:332-334.
28. Macaluso CJ, Bauer UE, Deeb LC, et al. Type 2 diabetes mellitus
among Florida children and adolescents, 1994 through 1998.
Public
Health Rep. 2002;117:373-379.
[PubMed: 12477919]
29. Keen H, Jarrett RJ. Environmental factors and genetic interactions.
In: Creutzfeld W, Kobberling J, Neel JV, eds. The Genetics
of Diabetes Mellitus. Berlin: Springer-Verlag; 1976:203-214.
30. Gottlieb MS. Diabetes in offspring and siblings of juvenile-
and maturity-onset-type diabetics.
J Chronic Dis. 1980;33:331-339.
[PubMed: 6989842]
31. Dahlquist G, Blom L, Tuvemo T, Nystrom L, Sandstrom A, Wall
S. The Swedish childhood diabetes study—results from a
nine year case register and a one year case-referent study indicating
that type 1 (insulin-dependent) diabetes mellitus is associated
with both type 2 (non-insulin-dependent) diabetes mellitus and autoimmune
disorders.
Diabetologia. 1989;32:2-6.
[PubMed: 2707516]
32. Li H, Lindholm E, Almgren P, Gustafsson A, et al. Possible
human leukocyte antigen-mediated genetic interaction between type
1 and type 2 diabetes.
J Clin Endocrinol Metab. 2001;86:574-582.
[PubMed: 11158011]
34. Rosenbloom AL. Obesity, insulin resistance, beta cell autoimmunity,
and the changing clinical epidemiology of childhood diabetes.
Diabetes
Care. 2003;26:2954-2956.
[PubMed: 14514609]
35. Atkinson MA. Thirty years of investigating the autoimmune
basis for type 1 diabetes: why canít we prevent or reverse
this disease?
Diabetes. 2005;54:1253-1263.
[PubMed: 15855308]
36. WHO Multinational Project for Childhood Diabetes. WHO Diamond
Project Group. Diabetes Care. 1990;13:1062-1068.
37. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte
R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide.
Diabetes Mondiale (DiaMond) Project Group.
Diabetes Care. 2000;23:1516-1526.
[PubMed: 11023146]
38. Kondrashova A, Reunanen A, Romanov A, et al. A six-fold
gradient in the incidence of type 1 diabetes at the eastern border
of Finland.
Ann Med. 2005;37:67-72.
[PubMed: 15902849]
39. LaPorte R, Matsushima M, Chang Y-F. Prevalence and incidence
of insulin-dependent diabetes. In: National Diabetes Data
Group: Diabetes in America, 2nd ed. Bethesda, MD: National
Institutes of Health, National Institute of Diabetes and Digestive
and Kidney Diseases; 1995:37-46.
40. Mimura G. Present status and future view of the genetics
of diabetes in Japan. In: Mimura G, Baba S, Goto W, Kobberling J,
eds. Clinical Genetics of Diabetes Mellitus, International
Congress Series 597. Amsterdam: Excerpta Medica; 1982:13-18.
41. Kitagawa T, Fugita, H, Hibi, I. A comparative study of the
epidemiology of IDDM in between Japan, Norway, Israel, and the United
States. Acta Paediatr Jpn. 1984;26:275-281.
42. Siemiatycki J, Colle E, Campbell S, Dewar R, Aubert D, Belmonte
MM. Incidence of IDDM in Montreal by ethnic group and by social
class and comparisons with ethnic groups living elsewhere.
Diabetes. 1988;37:1096-1102.
[PubMed: 3391344]
43. Gale EA. The rise of childhood type 1 diabetes in the 20th
century.
Diabetes. 2002;51:3353-3361.
[PubMed: 12453886]
44. Karvonen M, Tuomilehto J, Libman I, LaPorte R. A review
of the recent epidemiological data on the worldwide incidence of
type 1 (insulin-dependent) diabetes mellitus. World Health Organization DIAMOND
Project Group.
Diabetologia. 1993;36:883-892.
[PubMed: 8243865]
45. Diabetes Epidemiology Research International Group. Secular
trends in incidence of childhood IDDM in 10 countries. Diabetes. 1990;39:858-864.
46. Mauny F, Grandmottet M, Lestradet C, et al. Increasing trend
of childhood type 1 diabetes in Franche-Comte (France): analysis
of age and period effects from 1980 to 1998.
Eur JEpidemiol. 2005;20:325-329.
[PubMed: 15971504]
47. Pundziute-Lycka A, Dahlquist G, Urbonaite B, Zalinkevicius
R. Time trend of childhood type 1 diabetes incidence in Lithuania
and Sweden, 1983-2000.
Acta Paediatr. 2004;93:1519-1524.
[PubMed: 15513583]
48. Charkaluk ML, Czernichow P, Levy-Marchal C. Incidence data
of childhood-onset type I diabetes in France during 1988-1997: the
case for a shift toward younger age at onset.
Pediatr Res. 2002;52:859-862.
[PubMed: 12438661]
49. Feltbower RG, McKinney PA, Parslow RC, Stephenson CR, Bodansky
HJ. Type 1 diabetes in Yorkshire, UK: time trends in 0-14 and 15-29-year-olds,
age at onset and age-period-cohort modelling.
Diabet Med. 2003;20:437-441.
[PubMed: 12786676]
50. Kibirige M, Metcalf B, Renuka R, Wilkin T. Testing the accelerator
hypothesis (1): the relationship between body mass and age at diagnosis
of type 1 diabetes.
Diabetes Care. 2003;26:2865-2870
[PubMed: 14514593]
51. Weets I, Kaufman L, Van der Auwera B, et al. Seasonality
in clinical onset of type 1 diabetes in belgian patients above the
age of 10 is restricted to HLA-DQ2/DQ8-negative males,
which explains the male to female excess in incidence.
Diabetologia. 2004;47:614-621.
[PubMed: 15298337]
52. Fleeger F, Rogers KD, Drash A, Travis LB, Court JM, Rosenbloom
AL. Age, sex, and season of onset of childhood diabetes in different
geographic areas. Pediatrics. 1979;63:374-379.
53. Rosenbloom AL. Insulin responses of children with chemical
diabetes mellitus. N Engl J Med. 1970;282:1128-1231.
54. Rosenbloom AL, Hunt SS, Rosenbloom EK, Maclaren NK. Ten-year
prognosis of impaired glucose tolerance in siblings of patients
with insulin�dependent diabetes.
Diabetes. 1982;31:385-387.
[PubMed: 6759254]
55. Rosenbloom AL. Nature and nurture in the expression of diabetes
mellitus and its vascular manifestations.
Am J Dis Child. 1977;131:1154-1159.
[PubMed: 333901]
56. Falorni A, Ackefors M, Carlberg C, et al. Diagnostic sensitivity
of immunodominant epitopes of glutamic acid decarboxylase (GAD65)
autoantibodies in childhood IDDM.
Diabetologia. 1996;39:1091-1098.
[PubMed: 8877294]
57. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent
diabetes mellitus.
N Engl J Med. 1994;331:1428-1436.
[PubMed: 7969282]
58. Schatz D, Krischer J, Horne G, et al. Islet cell antibodies
predict insulin-dependent diabetes in United States school age children
as powerfully as in unaffected relatives.
J Clin Invest. 1994;93:2403-2407.
[PubMed: 8200974]
59. Winter WE, Harris N, Schatz D. Immunological markers in
the diagnosis and prediction of autoimmune type 1a diabetes. Clin
Diabetes. 2002;20:183-191.
60. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives
on disease pathogenesis and treatment.
Lancet. 2001;358:221-229.
[PubMed: 11476858]
61. Neufeld M, Maclaren NK, Riley WJ, et al. Islet cell and
other organ specific antibodies in US Caucasians and Blacks with
insulin-dependent diabetes mellitus.
Diabetes. 1980;29:589-592.
[PubMed: 7002675]
62. Rosenbloom AL. Autoantibodies to islet cells: comparison
of methods.
Lancet. 1983;1:72-73.
[PubMed: 6129408]
63. Achenbach P, Warncke K, Reiter J, et al. Stratification
of type 1 diabetes risk on the basis of islet autoantibody characteristics.
Diabetes. 2004;53:384-392.
[PubMed: 14747289]
64. Krischer JP, Schatz D, Riley WJ, et al. Insulin and islet
cell autoantibodies as time-dependent covariates in the development
of insulin-dependent diabetes: a prospective study in relatives.
J
Clin Endocrinol Metab. 1993;77:743-749.
[PubMed: 8370696]
65. Riley WJ, Maclaren NK, Krischer J, et al. A prospective
study of the development of diabetes in relatives of patients with
insulin-dependent diabetes.
N Engl J Med. 1990;323:1167-1172.
[PubMed: 2215594]
66. Group D-S. The Diabetes Prevention Trial Type 1 Diabetes
(DPT-1). Diabetes. 1994;43(suppl):159A.
67. Hyttinen V, Kaprio J, Kinnunen L, Koskenvuo M, Tuomilehto
J. Genetic liability of type 1 diabetes and the onset age among
22,650 young Finnish twin pairs: a nationwide follow-up study.
Diabetes. 2003;52:1052-1055.
[PubMed: 12663480]
68. Ginsberg-Fellner F, Witt ME, Fedun B, et al. Diabetes mellitus
and autoimmunity in patients with the congenital rubella syndrome. Rev
Infect Dis. 1985;7(suppl 1):S170-176.
69. Salminen K, Sadeharju K, Lonnrot M, et al. Enterovirus infections
are associated with the induction of beta-cell autoimmunity in a
prospective birth cohort study.
J Med Virol. 2003;69:91-98.
[PubMed: 12436483]
70. Salminen KK, Vuorinen T, Oikarinen S, et al. Isolation of
enterovirus strains from children with preclinical type 1 diabetes.
Diabet
Med. 2004;21:156-164.
[PubMed: 14984451]
71. McKinney PA, Okasha M, Parslow RC, et al. Early social mixing
and childhood type 1 diabetes mellitus: a case-control study in
Yorkshire, UK.
Diabet Med. 2000;17:236-242.
[PubMed: 10784230]
72. Zipitis CS, Akobeng AK. Vitamin D supplementation in early
childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch
Dis Child. 2008; epub doi: 10.1136/ADC 2007.128579.
73. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Childhood vaccination
and type 1 diabetes.
N Engl J Med. 2004;350:1398-1404.
[PubMed: 15070789]
74. Karjalainen J, Martin JM, Knip M, et al. A bovine albumin
peptide as a possible trigger of insulin-dependent diabetes mellitus.
N
Engl J Med. 1992;327:302-307.
[PubMed: 1377788]
75. Norris JM, Beaty B, Klingensmith G, et al. Lack of association
between early exposure to cowís milk protein and beta-cell
autoimmunity. Diabetes Autoimmunity Study in the Young (DAISY).
JAMA. 1996;276:609-614.
[PubMed: 8773632]
76. Akerblom HK, Virtanen SM, Ilonen J, et al. Dietary manipulation
of beta cell autoimmunity in infants at increased risk of type 1
diabetes: a pilot study.
Diabetologia. 2005;48:829-837.
[PubMed: 15838685]
77. Wilson DM, Buckingham B. Prevention of type 1a diabetes
mellitus.
Pediatr Diabetes. 2001;2:17-24.
[PubMed: 15016206]
78. Hyoty H, Taylor KW. The role of viruses in human diabetes.
Diabetologia. 2002;45:1353-1361.
[PubMed: 12378375]
79. Dahlquist GG, Ivarsson S, Lindberg B, Forsgren M. Maternal
enteroviral infection during pregnancy as a risk factor for childhood
IDDM. A population-based case-control study.
Diabetes. 1995;44:408-413.
[PubMed: 7698508]
80. Honeyman MC, Coulson BS, Stone NL, et al. Association between
rotavirus infection and pancreatic islet autoimmunity in children
at risk of developing type 1 diabetes.
Diabetes. 2000;49:1319-1324.
[PubMed: 10923632]
81. Wolfsdorf J, Craig ME, Daneman D, et al. Diabetic ketoacidosis.
ISPAD guidelines.
Pediatr Diabetes. 2007;8:28-42.
[PubMed: 17341289]
82. Chernow B, Rainey TG, Heller R, Clapper M, Labow J. Marked
stress hyperglycemia in a child.
Crit Care Med. 1982;10:696-697.
[PubMed: 7116895]
83. Boulware SD, Tamborlane WV. Not all severe hyperglycemia
is diabetes.
Pediatrics. 1992;89:330-332.
[PubMed: 1734406]
84. Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris AN.
Drug-induced disorders of glucose tolerance.
Ann Intern
Med. 1993;118:529-539.
[PubMed: 8442624]
85. Henriksen JE, Alford F, Ward GM, Beck-Nielsen H. Risk and
mechanism of dexamethasone-induced deterioration of glucose tolerance
in non-diabetic first-degree relatives of NIDDM patients.
Diabetologia.
1997;40:1439-1448.
[PubMed: 9447952]
86. American Diabetes Association. Position statement: hyperglycemic
crises in patients with diabetes mellitus. Diabetes Care. 2001;24(suppl):S83-S90.
87. Burge MR, Hardy KJ, Schade DS. Short-term fasting is a mechanism
for the development of euglycemic ketoacidosis during periods of
insulin deficiency.
J Clin Endocrinol Metab. 1993;76:1192-1198.
[PubMed: 8496310]
88. Pinkey JH, Bingley PJ, Sawtell PA, Dunger DB, Gale EA. Presentation
and progress of childhood diabetes mellitus: a prospective population-based
study. The Bart’s-Oxford Study Group.
Diabetologia. 1994;37:70-74.
[PubMed: 8150233]
89. Lévy-Marchal C, Patterson CC, Green A, on behalf
of the EURODIAB ACE study group. Geographical variation of presentation
at diagnosis of type 1 diabetes in children: the EURODIAB Study. Diabetologia. 2001;44(suppl
3):B75-B80.
90. Bui TP, Werther GA, Cameron EJ. Trends in diabetic ketoacidosis
in childhood and adolescence: a 15-yr experience.
Pediatr
Diabetes. 2002;3:82-88.
[PubMed: 15016161]
91. Jackson W, Hoffman PL, Robinson EM, Elliot RB, Pilcher CC,
Cutfield WS. The changing presentation of children with newly diagnosed
type 1 diabetes mellitus.
Pediatr Diabetes. 2001;2:154-159.
[PubMed: 15016180]
92. Vanelli M, Chiari G, Ghizzoni L, Costi G, Giacalone T, Chiarelli
F. Effectiveness of a prevention program for diabetic ketoacidosis
in children. An 8-year study in schools and private practices.
Diabetes
Care. 1999;22:7-9.
[PubMed: 10333896]
93. Mallare JT, Cordice CC, Ryan BA, Carey DE, Kreitzer PM,
Frank GR. Identifying risk factors for the development of diabetic
ketoacidosis in new onset type 1 diabetes mellitus.
Clin
Pediatr. 2003;42:591-597.
[PubMed: 14552517]
94. Maniatis AK, Goehrig SH, Gao D, Rewers A, Walravens P, Klingensmith
G. Increased incidence and severity of diabetic ketoacidosis among
uninsured children with newly diagnosed type 1 diabetes mellitus.
Pediatr
Diabetes. 2005; 6:79-83.
[PubMed: 15963034]
95. Neu A, Willasch A, Ehehalt S, Hub R, Ranke MB, on behalf
of the DIARY group Baden-Wuerttemberg. Ketoacidosis at onset of
type 1 diabetes mellitus in children-frequency and clinical presentation.
PediatrDiabetes. 2003;4:77-80.
[PubMed: 14655263]
96. Roche EF, Menon A, Gill D, Hoey H. Clinical presentation
of type 1 diabetes.
Pediatr Diabetes. 2005;6:75-70.
[PubMed: 15963033]
97. Rewers A, Chase HP, Mackenzie T, et al. Predictors of acute
complications in children with type 1 diabetes.
JAMA. 2002;287:2511-2518.
[PubMed: 12020331]
98. Giordano B, Rosenbloom AL, Heller DR, Weber FT, Gonzales
R, Grgic A. Regional services for children and youth with diabetes. Pediatrics. 1977;60:492-498.
99. Golden MP, Herrold AJ, Orr DP. An approach to prevention
of recurrent diabetic ketoacidosis in the pediatric population.
J
Pediatr. 1985;107:195-200.
[PubMed: 3926977]
100. Foster DW, McGarry JD. The metabolic derangements and treatment
of diabetic ketoacidosis.
N Engl J Med. 1983;309:159-169.
[PubMed: 6408476]
101. Levitsky L, Ekwo E, Goselink CA, Solomon EL, Aceto T. Death
from diabetes (DM) in hospitalized children (1970-1998) [abstract] Pediatr
Res. 1991;29:A195.
102. Curtis JR, To T, Muirhead S, Cummings E, Daneman D. Recent
trends in hospitalization for diabetic ketoacidosis in Ontario children.
Diabetes
Care. 2002;25:1591-1596.
[PubMed: 12196432]
103. Lawrence SE, Cummings EA, Gaboury I, Daneman D. Population-based
study of incidence and risk factors for cerebral edema in pediatric
diabetic ketoacidosis.
J Pediatr. 2005;146:688-692.
[PubMed: 15870676]
104. Edge JA, Ford-Adams ME, Dunger DB. Causes of death in children
with insulin-dependent diabetes 1990-96.
Arch Dis Child. 1999;81:318-323.
[PubMed: 10490436]
105. Rosenbloom AL. Intracerebral crises during treatment of
diabetic ketoacidosis.
Diabetes Care. 1990;13:22-33.
106. Edge JA, Hawkins MM, Winter DL, Dunger DB. The risk and outcome
of cerebral oedema developing during diabetic ketoacidosis.
Arch
Dis Child. 2001;85:16-22.
[PubMed: 2105195]
107. Glaser N, Barnett P, McCaslin I, et al. Risk factors for
cerebral edema in children with diabetic ketoacidosis.
N
Engl J Med. 2001;344:264-269.
[PubMed: 11172153]
108. Lipton R, Good G, Mikhailov T, Freels S, Donoghue E. Ethnic
differences in mortality from insulin-dependent diabetes mellitus
among people less than 25 years of age.
Pediatrics. 1999;103:952-956.
[PubMed: 10224171]
109. Casteels K, Beckers D, Wouters C, Van Geet C. Rhabdomyolysis
in diabetic ketoacidosis.
Pediatr Diabetes. 2003;4:29-31.
[PubMed: 14655521]
110. Buckingham BA, Roe TF, Yoon J-W. Rhabdomyolysis in diabetic
ketoacidosis.
Am J Dis Child. 1981;135:352-354.
[PubMed: 6782859]
111. Moye J, Rosenbloom AL, Silverstein J. Clinical predictors
of mucormycosis in type 1 diabetes in children.
J Ped Endocrinol
Metab. 2002;15:1001-1004.
[PubMed: 12199326]
112. Haddad NG, Croffie JM, Rugster EA. Pancreatic enzyme elevations
in children with diabetic ketoacidosis.
J Pediatr. 2004;145:122-124.
[PubMed: 15238920]
113. Gutierrez JA, Bagatell R, Samson MP, Theodorou AA, Berg
RA. Femoral central venous catheter-associated deep venous thrombosis
in children with diabetic ketoacidosis.
Crit Care Med. 2003;31:80-83.
[PubMed: 12544997]
114. Worly JM, Fortenberry JD, Hansen I, Chambliss CR, Stockwell
J. Deep venous thrombosis in children with diabetic ketoacidosis
and femoral central venous catheters. Pediatrics. 2004;
113:57-60.
115. Zeitler P, Thiede A, Muller HL. Prospective study on plasma
clotting parameters in diabetic children-no evidence for specific
changes in coagulation system.
Exp Clin Endorinol Diabetes. 2001;109:146-152.
[PubMed: 11409296]
116. Carl CF, Hoffman WH, Passmore GG, et al. Diabetic ketoacidosis
promotes a prothrombotic state.
Endo Res. 2003;29:73-82.
[PubMed: 12665320]
117. De Stefano V, Rossi E, Paciaroni K, Leone G. Screening
for inherited thrombophilia: indications and therapeutic implications. Haematologica. 2002;7:1095-1108.
118. Haller MJ, Valladares A, Rosenbloom AL. Arterial thrombosis
resulting in amputation in a child with poorly controlled type 1
diabetes and heterozygous factor V Leiden mutation.
Pediatr
Diabetes. 2006;7:229-231.
[PubMed: 16911011]
119. Roberts MD, Slover RH, Chase HP. Diabetic ketoacidosis
with intracerebral complications.
Pediatr Diabetes. 2001;2:109-114.
[PubMed: 15016193]
120. Keane S, Gallagher A, Aykroyd S, McShane MA, Edge JA. Cerebral
venous thrombosis during diabetic ketoacidosis.
Arch Dis
Child. 2002;86:204-206.
[PubMed: 11861244]
121. Rosenbloom AL. Fatal cerebral infarctions in diabetic ketoacidosis
in a child with previously unknown heterozygosity for factor V Leiden
deficiency.
J Pediatr. 2004;145:561-562.
[PubMed: 15480386]
122. Yoon J-W, Austin M, Onodera T, Notkins AL. Virus-induced
diabetes mellitus.
N Engl J Med. 1979; 300:1173-1179.
[PubMed: 219345]
123. Cooper RM, Turner RA, Hutaff L, Prichard R. Diabetic keto-acidosis
complicated by disseminated intravascular coagulation.
South
Med J. 1973;66:653-657.
[PubMed: 4196649]
124. Bonfanti R, Bognetti E, Meschi F, Medaglini S, D’Angelo
A, Chiumello G. Disseminated intravascular coagulation and severe
peripheral neuropathy complicating ketoacidosis in a newly diagnosed
diabetic child.
Acta Diabetol. 1994;31:173-174.
[PubMed: 7827359]
125. Carvalho KS, Bodensteiner JB, Connolly PJ, Garg BP. Cerebral
venous thrombosis in children.
J Child Neurol. 2001;16:574-580.
[PubMed: 11510928]
126. Young E, Bradley RF. Cerebral edema with irreversible coma
in severe diabetic ketoacidosis.
N Engl J Med. 1967;276:665-669.
[PubMed: 4959859]
127. Rosenbloom AL, Riley WJ, Weber FT, Malone JI, Donnelly
WH. Cerebral edema complicating diabetic ketoacidosis in childhood.
J
Pediatr. 1980;96:357-361.0
[PubMed: 6767008]
128. Bello FA, Sotos JF. Cerebral oedema in diabetic ketoacidosis
in children [letter].
Lancet 1990;
336:64.
[PubMed: 1973254]
129. Brown TB. Cerebral oedema in childhood diabetic ketoacidosis:
Is treatment a factor?
Emerg Med J. 2004;21:141-144.
[PubMed: 14988335]
130. Dunger DB, Edge JA. Predicting cerebral edema during diabetic
ketoacidosis. [editorial]
N Engl
J Med. 2001;344:302-303.
[PubMed: 11172161]
131. Azzopardi J, Gatt A, Zammit A, Albert G. Lack of evidence
of cerebral edema in adults treated for diabetic ketoacidosis with
fluids of different tonicity.
Diabetes Res Clin Pract. 2002;57:87-92.
[PubMed: 12062852]
132. Carroll P, Matz R. Uncontrolled diabetes mellitus in adults:
experience in treating diabetic ketoacidosis and hyperosmolar nonketotic
coma with low dose insulin and a uniform treatment regimen.
Diabetes
Care. 1983;6:579-585.
[PubMed: 6418494]
133. Muir AB, Quisling RG, Yang MCK, Rosenbloom AL. Cerebral
edema in childhood diabetic ketoacidosis. Natural history, radiographic
findings, and early identification.
Diabetes Care. 2004;27:1541-1546.
[PubMed: 15220225]
134. Marcin JP, Glaser N, Barnett P, et al. Factors associated
with adverse outcomes in children with diabetic ketoacidosis-related
cerebral edema.
J Pediatr. 2002;141:793-797.
[PubMed: 12461495]
135. Pappius HM. Fundamental aspects of brain edema. In: Vinkin
PJ, Bruyn GW, eds. Handbook of Clinical Neurology,
vol 16, part 1: Tumors of the Brain and Skull.
Amsterdam, North Holland Publishing Co.; 1974:167-185.
136. Salem MAK, Matta LF, Tantawy AAG, Hussein M, Gad GI. Single
photon emission tomography (SPECT) study of regional cerebral blood
flow in normoalbuminuric children and adolescents with type 1 diabetes.
Pediatr
Diabetes. 2002;3:155-162.
[PubMed: 15016156]
137. Krane EJ, Rockoff MA, Wallman JK, Wolfsdorf JI. Subclinical
brain swelling in children during treatment of diabetic ketoacidosis.
N
Engl J Med. 1985;312:1147-1151.
[PubMed: 3920521]
138. Durr JA, Hoffman WH, Sklar AH, el Gammal T, Steinhart CM.
Correlates of brain edema in uncontrolled IDDM.
Diabetes. 1992;41:627-632.
[PubMed: 1568533]
139. Glaser N, Wooten-Gorges SL, Marcin JP, et al. Mechanism
of cerebral edema in children with diabetic ketoacidosis.
J
Pediatr 2004;145:164-171.
[PubMed: 15289761]
140. Glaser NS, Wooten-Gorges SL, Buonocore MH, et al. Frequency
of sub-clinical cerebral edema in children with diabetic ketoacidosis.
Pediatr
Diabetes. 2006;7:75-80.
[PubMed: 16629712]
141. Wooten-Gorges SL, Buonocore MH, Kuppermann N, et al. Detection
of cerebral β-hydroxy butyrate, acetoacetate, and
lactate on proton NMR spectroscopy in children with diabetic ketoacidosis. Am
J Neuroradiol. 2005;26:1286-1291.
142. Cameron FJ, Kean MJ, Wellard RM, et al. Insights into the
acute cerebral metabolic changes associated with childhood diabetes.
Diabet
Med. 2005;22:648-653.
[PubMed: 15842524]
143. Hoffman WH, Burek CL, Waller JL, Fisher LE, Khichi M, Mellick
LB. Cytokine response to diabetic ketoacidosis and its treatment.
Clin
Immunol. 2003;108:175-81.
[PubMed: 14499240]
144. Fiordalisi I, Novotny WE, Holbert D, Finberg L, Harris
GD, Critical Care Management Group. An 18-yr prospective study of
pediatric diabetic ketoacidosis: an approach to minimizing the risk
of brain herniation during treatment.
Pediatr Diabetes.
2007;8:142-149.
[PubMed: 17550424]
145. Zornow MH, Oh YS, Scheller MS. A comparison of the cerebral
and haemodynamic effects of
mannitol and hypertonic saline in an
animal model of brain injury.
Acta Neurochir Suppl. 1990;51:324325.
146. Qureshi AI, Wilson DA, Traystman RJ. Treatment of elevated
intracranial pressure in experimental intracerebral hemorrhage:
comparison between
mannitol and hypertonic saline.
Neurosurgery. 1999;44:1055-1063.
[PubMed: 10232539]
147. Freshman SP, Battistella FD, Matteucci M, Wisner DH. Hypertonic
saline (7.5%) versus
mannitol: a comparison for treatment
of acute head injuries.
J Trauma. 1993;35:344-348.
[PubMed: 8371290]
148. Berger S, Schurer L, Hartl R, Messmer K, Baethmann A. Reduction
of post-traumatic intracranial hypertension by hypertonic/hyperoncotic
saline/dextran and hypertonic
mannitol.
Neurosurgery. 1995;37:98-107.
[PubMed: 8587698]
149. Gemma M, Cozzi S, Tommasino C, et al. 7.5% hypertonic
saline versus 20%
mannitol during elective neurosurgical
supratentorial procedures.
J Neurosurg Anesthesiol. 1997;9:329-334.
[PubMed: 9339405]
150. Worthley LI, Cooper DJ, Jones N. Treatment of resistant
intracranial hypertension with hypertonic saline. Report of two
cases.
J Neurosurg. 1988;68:478-481.
[PubMed: 3343621]
151. Qureshi AL, Suarez JI. Use of hypertonic saline solutions
in treatment of cerebral edema and intracranial hypertension.
Crit
Care Med. 2000;28:3301-3313.
[PubMed: 11008996]
152. Curtis JR, Bohn D, Daneman D. Use of hypertonic saline
in the treatment of cerebral edema in diabetic ketoacidosis (DKA).
Pediatr
Diabetes. 2001;2:191-194.
[PubMed: 15016186]
153. Shapiro HM, Drummond JC. Neurosurgical anesthesia. In:
Miller RD, ed. Anesthesia, 3rd ed. New York: Churchill
Livingstone; 1990:1913-1914.
154. Muizelaar JP, Marmarou A, Ward JD. et al. Adverse effects
of prolonged hyperventilation in patients with severe head injury:
a randomized clinical trial.
J Neurosurg. 1991;75:731-739.
[PubMed: 1919695]
155. Bonadio WA, Gutzeit MF, Losek JD, Smith DS. Outpatient
management of diabetic ketoacidosis.
Am J Dis Child. 1988;142:448-450.
[PubMed: 3126645]
156. Linares MY, Schunk JE, Lindsay R. Laboratory presentation
in diabetic ketoacidosis and duration of therapy.
Pediatr
Emerg Care. 1996;12:347-151.
[PubMed: 8897542]
157. Chase HP, Garg SK, Jelley DH. Diabetic ketoacidosis in
children and the role of outpatient management.
Pediatr
Rev. 1990;11:297-304.
[PubMed: 2114610]
158. Rosenbloom AL, Schatz DA. Diabetic ketoacidosis in childhood.
Pediatr
Ann. 1994;23:284-288.
[PubMed: 8078704]
159. Koves IH, Neutze J, Donath S, et al. The accuracy of clinical
assessment of dehydration during diabetic ketoacidosis in childhood.
Diabetes
Care. 2004;27:2485-2487.
[PubMed: 15451920]
160. Teasdale G, Jennett B. Assessment of coma and impaired
consciousness. A practical scale. Lancet. 1974;ii:81-84.
161. Malone JI, Brodsky SJ. The value of electrocardiogram monitoring
in diabetic ketoacidosis.
Diabetes Care. 1980;3:543-547.
[PubMed: 6780284]
162. Soler NG, Bennett MA, Fitzgerald MG, Malins JM. Electrocardiogram
as a guide to potassium replacement in diabetic ketoacidosis.
Diabetes. 1974;23:610-615.
[PubMed: 4210168]
163. Schatz DA, Rosenbloom AL. Diabetic ketoacidosis: management
tactics in young patients. J Crit Illness. 1988;3:29-41.
164. Malone JI, Root AW. Plasma free insulin concentrations:
keystone to effective management of diabetes mellitus in children.
J
Pediatr. 1981;99:862-867.
[PubMed: 7031209]
165. Rosenbloom AL, Hanas R. Diabetic ketoacidosis (DKA): treatment
guidelines.
Clin Pediatr. 1996;35:261-266.
[PubMed: 8804545]
166. Katz MA. Hyperglycemia-induced hyponatremia—calculation
of expected serum sodium depression.
N Engl J Med. 1973;289:843-844.
[PubMed: 4763428]
167. Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating
the correction factor for hyperglycemia.
Am J Med. 1999;106:399-403.
[PubMed: 10225241]
168. Adrogue HJ, Eknoyan G, Suki WK. Diabetic ketoacidosis:
role of the kidney in the acid-base homeostasis re-evaluated.
Kidney
Int. 1984;25:591-598.
[PubMed: 6434787]
169. Oh MS, Carroll HJ, Uribarri J. Mechanism of normochloremic
and hyperchloremic acidosis in diabetic ketoacidosis.
Nephron. 1990;54:1-6.
[PubMed: 2104963]
170. Poirier MP, Greer D, Satin-Smith M. A prospective study
of the “two bag system” in diabetic ketoacidosis
management.
Clin Pediatr. 2004;43:809-813.
[PubMed: 15583776]
171. Rosenbloom AL, Ongley JP. Serum calcium phosphorus and
magnesium decrement during oral glucose tolerance testing: alteration
in pre-clinical and overt diabetes mellitus in childhood. In: Catin M,
Selig M, eds. Magnesium in Health and Disease. Jamaica.
NY: Spectrum Publishers Inc.; 1980:297-304.
172. Edge J, Jakes R, Roy Y, et al. The UK prospective study
of cerebral oedema complicating diabetic ketoacidosis. Arch
Dis Child. 2005;90(suppl 11):A2-A3.
173. Fisher J, Shahshahani M, Kitabchi A. Diabetic ketoacidosis:
low dose insulin therapy by various routes.
N Engl J Med. 1977;297:238-243.
[PubMed: 406561]
174. Sacks HS, Shahshahani M, Kitabchi AE, Fisher JN, Young
RT. Similar responsiveness of diabetic ketoacidosis to low-dose
insulin by intramuscular injection and albumin-free infusion.
Ann
Intern Med. 1979;90:36-42.
[PubMed: 105656]
175. Umpierrez GE, Latif K, Stoever J, et al. Efficacy of subcutaneous
insulin lispro versus continuous intravenous regular insulin for
the treatment of patients with diabetic ketoacidosis.
Am
J Med. 2004;117:291-296.
[PubMed: 15336577]
176. Umpierrez GE, Cuervo R, Karabell A, Latif K, Freire AX,
Kitabchi AE. Treatment of diabetic ketoacidosis with subcutaneous
insulin aspart.
Diabetes Care. 2004;27:1873-1878.
[PubMed: 15277410]
177. Manna TD, Steinmetz L, Campos PR, et al. Subcutaneous use
of a fast-acting insulin analog. An alternative treatment for pediatric
patients with diabetic ketoacidosis.
Diabetes Care. 2005;28:1856-1861.
[PubMed: 16043723]
178. Malone JI, Rosenbloom AL, Grgic A, Weber FT. The role of
urine sugar in diabetic management.
Am J Dis Child. 1976;130:1324-1327.
[PubMed: 998574]
179. Malone JI, Hellrung JM, Malphus EW, Rosenbloom AL, Grgic
A, Weber FT. Good diabetic controlóa study in mass delusion.
J
Pediatr. 1976;88:943-947.
[PubMed: 1271192]
180. Grgic A, Rosenbloom AL, Weber FT, Giordano B, Malone JI,
Shuster JJ. Joint contractureócommon manifestation of childhood
diabetes mellitus.
J Pediatr. 1976;88:584-588.
[PubMed: 1255316]
181. Sonksen PH, Judd SL, Lowy C. Home monitoring of blood-glucose.
Method for improving diabetic control.
Lancet. 1978;1:729-732.
[PubMed: 76745]
182. Rosenbloom A, Silverstein JH, Riley WJ, et al. Total glycosylated
hemoglobin estimation in the management of children and youth with
diabetes. Bull Int Study Group Diabetes Child Adolesc. 1980;4:24-25.
183. DCCT Research Group. The effect of intensive treatment
of diabetes on the development and progression of long-term complications
in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
184. Harkavy J, Johnson SB, Silverstein J, Spillar R, McCallum
M, Rosenbloom A. Who learns what at diabetes camp?
J Pediatr
Psychol. 1983;8:143-153.
[PubMed: 6875762]
186. WangY-C, Stewart S, Tull E, White P. Improved glycemic
control in adolescents with type 1 diabetes mellitus who attend
diabetes camp. Pediatr Diabetes. 2007;9:29-34.
187. Gallego PH, Wiltshire E, Donaghue KC. Identifying
children at particular risk of long-term complications. PediatrDiabetes 2007;8(suppl
6):40-48.
188. Ferguson SC, Blane A, Wardlaw J, et al. Influence of an
early-onset type 1 diabetes on cerebral structure and cognitive
function.
Diabetes Care, 2005;28:1431-1437.
[PubMed: 15920064]
189. Dahlquist G, Kallen B. School performance in children
with type 1 diabetes-a population-based register study. Diabetologia, 2007;50:
957-964.
190. American Diabetes Association. Diabetes care in the school
and day care setting. Diabetes Care, 2005;28(suppl
1):S43-S49.
191. American Diabetes Association. Diabetes care at diabetes
camps. Diabetes Care. 2005;28(suppl 1):S50-S52.
192. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN,
for the DCCT/EDIC Research Group. The effect of glycemic
exposure on the risk of microvascular complications in the Diabetes
Control and Complications Trial—revisited. Diabetes.
2008, Jan 25 [Epub ahead of print] DOI:
10.2337/db07-1618.
193. Davis S, Alonso MD. Hypoglycemia as a barrier to glycemic
control.
J Diabetes Complicat. 2004;18:60-68.
[PubMed: 15019602]
194. Rosenbloom A, Frias JL. Diabetes mellitus, short stature,
and joint stiffnessóa new syndrome.Clin Res. 1974;22:92A.
195. Rosenbloom AL. Limited joint mobility in insulin dependent
childhood diabetes.
Eur J Pediatr. 1990;149:380-388.
[PubMed: 2185025]
196. Rosenbloom AL, Silverstein JH, Lezotte DC, Richardson K,
McCallum M. Limited joint mobility in childhood diabetes mellitus
indicates increased risk for microvascular disease.
N Engl
J Med. 1981;305:191-194.
[PubMed: 7242598]
197. Silverstein JH, Gordon G, Pollock BH. Rosenbloom AL. Long
term glycemic control influences the development of limited joint
mobility in type 1 diabetes.
J Pediat. 1998;132:944-947.
[PubMed: 9627583]
198. Infante JR, Rosenbloom AL, Silverstein JH, Garzarella L,
Pollock BH. Changes in frequency and severity of limited joint mobility
in children with type 1 diabetes mellitus between 1976-78 and 1998.
J
Pediatr. 2001;138:33-37.
[PubMed: 11148509]
199. Verrotti A, Chiarelli F, Amerio P, Morgese G. Necrobiosis
lipoidica diabeticorum in children and adolescents: a clue for underlying
renal and retinal disease.
Pediatr Dermatol. 1995;12:220-223.
[PubMed: 7501550]
200. Kelly WF, Nicholas J, Adams J, Mahmood R. Necrobiosis lipoidica
diabeticorum: association with background retinopathy, smoking,
and proteinuria. A case controlled study.
Diabet Med. 1993;10:725-728.
[PubMed: 8261754]
201. Raile K, Noelle V, Landgraf R, Schwarz HP. Insulin antibodies
are associated with lipoatrophy but also with lipohypertrophy in
children and adolescents with type 1 diabetes.
Exp Clin
Endocrinol Diabetes. 2001;109:393-396.
[PubMed: 11748486]
202. Arranz A, Andia V, Lopez-Guzman A. A case of lipoatrophy
with lispro insulin without insulin pump therapy.
Diabetes
Care. 2004;27:625-626.
[PubMed: 14747261]
203. Griffin ME, Feder A, Tamborlane WV. Lipoatrophy associated
with lispro insulin in insulin pump therapy: an old complication,
a new cause?
Diabetes Care. 2001;24:174.
[PubMed: 11194227]
204. Roper NA, Bilous RW. Resolution of lipohypertrophy following
change of short-acting insulin to insulin lispro (Humalog).
Diabet
Med. 1998;15:1063-1064.
[PubMed: 9868982]
205. Kordonouri O, Lauterborn R, Deiss D. Lipohypertrophy in
young patients with type 1 diabetes.
Diabetes Care. 2002;25:634.
[PubMed: 11874968]
206. Young RJ, Hannan WJ, Frier BM, Steel JM, Duncan LJ. Diabetic
lipohypertrophy delays insulin absorption.
Diabetes Care. 1984;7:479-480.
[PubMed: 6389062]
207. Lang-Muritano M, La Roche GR, Stevens JL, Gloor BR, Schoenle
EJ. Acute cataracts in newly diagnosed IDDM in five children and
adolescents.
Diabetes Care. 1995;18:1395-1396.
[PubMed: 8721945]
208. Tattersall RB, Pyke DA. Growth in diabetic children. Studies
in identical twins.
Lancet. 1973;2:1105-1109.
[PubMed: 4128010]
209. Kanumakala S, Dabadghao P, Carlin JB, Vidmar S, Cameron
FJ. Linear growth and height outcomes in children with early onset
type 1 diabetes mellitusóa 10-year longitudinal study.
Pediatr.
Diabetes. 2002;3:189-193.
[PubMed: 15016146]
210. Lebl J, Schober E, Zidek T, et al. Growth data in large
series of 587 children and adolescents with type 1 diabetes mellitus.
Endocr
Regul. 2003;37:153-161.
[PubMed: 14986721]
211. Menon RK, Arslanian S, May B, Cutfield WS, Sperling MA.
Diminished growth hormone-binding protein in children with insulin-dependent
diabetes mellitus.
J Clin Endocrinol Metab. 1992;74:934-938.
[PubMed: 1548360]
212. Massa G, Dooms L, Bouillon R, Vanderschueren-Lodeweyckx
M. Serum levels of growth hormone-binding protein and insulin-like
growth factor I in children and adolescents with type 1 (insulin-dependent)
diabetes mellitus.
Diabetologia. 1993;36:239-243.
[PubMed: 8462773]
213. Munoz MT, Barrios V, Pozo J, Argente J. Insulin-like growth
factor I, its binding proteins 1 and 3, and growth hormone-binding
protein in children and adolescents with insulin-dependent diabetes mellitus:
clinical implications.
Pediatr Res. 1996;39:992-998.
[PubMed: 8725260]
214. Bereket A, Lang CH, Wilson TA. Alterations in the growth
hormone-insulin-like growth factor axis in insulin dependent diabetes
mellitus.
Horm Metab Res. 1999;31:172-181.
[PubMed: 10226799]
215. Mauriac P. Gros ventre, hepatomegalie, troubles de croissance
chez les enfants diabetiques traites depuis plusiers annee par líinsuline.Gaz
Hebd Med Bordeaux. 1930;26:402-410.
216. Marble A, White P, Bogan I, Smith R. Enlargement of the
liver in diabetic childre: I. Its incidence etiology and nature. Arch
Intern Med. 1938;62:740-750.
217. Rosenbloom A, Clark DW. Excessive insulin treatments and
the Somogyi effect. In: Pickup J, ed. Difficult Diabetes. Oxford:
Blackwell; 1985:103-131.
218. Dorchy H, van Vliet G, Toussaint D, Ketelbant-Balasse P,
Loeb H. Mauriac syndrome: three cases with retinal angiofluorescein
study.
Diabet Metab. 1979;5:195-200.
[PubMed: 499634]
219. Winter RJ, Phillips LS, Green OC, Traisman HS. Somatomedin
activity in the Mauriac syndrome.
J Pediatr. 1980;97:598-600.
[PubMed: 7420224]
220. Kordonouri O, Klinghammer A, Lang EB, Gruters-Kieslich
A, Grabert M, Holl RW. Thyroid autoimmunity in children and adolescents
with type 1 diabetes: a multicenter survey.
Diabetes Care. 2002;25:1346-1350.
[PubMed: 12145233]
221. Silverstein J, Klingensmith G, Copeland K, et al. Care
of children and adolescents with type 1 diabetes: a statement of
the American Diabetes Association.
Diabetes Care. 2005;28:186-212.
[PubMed: 15616254]
222. Freemark M, Levitsky LL. Screening for celiac disease in
children with type 1 diabetes: two views of the controversy.
Diabetes
Care. 2003; 26:1932-1939.
[PubMed: 12766138]
223. Colton P, Olmsted M, Daneman D, Rydall A, Rodin G. Disturbed
eating behavior and eating disorders in preteen and early teenage
girls with type 1 diabetes: a case-controlled study.
Diabetes
Care. 2004;27:1654-1659.
[PubMed: 15220242]
224. Affenito SG, Adams CH. Are eating disorders more prevalent
in females with type 1 diabetes mellitus when the impact of insulin
omission is considered?
Nutr Rev. 2001;59:179-182.
[PubMed: 11444595]
225. Brownlee M. The pathobiology of diabetic complications:
a unifying mechanism.
Diabetes. 2005;54:1615-1625.
[PubMed: 15919781]
226. DCCT/EDIC Research Group. Sustained effect of
intensive treatment of type 1 diabetes mellitus on development and
progression of diabetic nephropathy: the Epidemiology of Diabetes
Interventions and Complications (EDIC) study. JAMA. 2003;290:2159-2167.
227. Greene DA, Lattimer SA, Sima AA.
Sorbitol, phosphoinositides,
and sodium-potassium-ATPase in the pathogenesis of diabetic complications.
N
Engl J Med. 1987;316:599-606.
[PubMed: 3027558]
228. Lee P, Jenkins A, Bourke C, et al. Prothrombotic and antithrombotic
factors are elevated in patients with type 1 diabetes complicated
by microalbuminuria.
Diabet Med. 1993;10:122-128.
[PubMed: 8458188]
229. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud
U, Keen H. Microalbuminuria as a predictor of clinical nephropathy
in insulin-dependent diabetes mellitus. Lancet. 1982;i:1430-1432.
230. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers
RE, Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk
factors and glycemic threshold.
Kidney Int. 2001;60:219-227.
[PubMed: 11422754]
231. Twyman S, Rowe D, Mansell P, Schapira D, Betts P, Leatherdale
B. Longitudinal study of urinary albumin excretion in young diabetic
patientsóWessex Diabetic Nephropathy Project.
Diabet
Med. 2001;18:402-408.
[PubMed: 11472452]
232. Santilli F, Spagnoli A, Mohn A, et al. Increased vascular
endothelial growth factor serum concentrations may help to identify
patients with onset of type 1 diabetes during childhood at risk
for developing persistent microalbuminuria.
J Clin Endocrinol
Metab. 2001;86:3871-3876.
[PubMed: 11502826]
233. Olsen BS, Sjolie A, Hougaard P, et al. A 6-year nationwide
cohort study of glycaemic control in young people with type 1 diabetes.
Risk markers for the development of retinopathy, nephropathy and
neuropathy. Danish Study Group of Diabetes in Childhood.
J
Diabetes Complicat. 2000;14:295-300.
[PubMed: 11120452]
234. Levy-Marchal C, Sahler C, Cahane M, Czernichow P. Risk
factors for microalbuminuria in children and adolescents with type
1 diabetes.
J Pediatr Endocrinol Metab. 2000;13:613-620.
[PubMed: 10905385]
235. Warram JH, Scott LJ, Hanna LS, et al. Progression of microalbuminuria
to proteinuria in type 1 diabetes: nonlinear relationship with hyperglycemia.
Diabetes.
2000;49:94-100.
[PubMed: 10615955]
236. Orchard TJ, Forrest KY, Kuller LH, Becker DJ. Lipid and
blood pressure treatment goals for type 1 diabetes: 10-year incidence
data from the Pittsburgh Epidemiology of Diabetes Complications Study.
Diabetes
Care. 2001;24:1053-1059.
[PubMed: 11375370]
237. Chiarelli F, Pomilio M, Mohn A, et al. Homocysteine levels
during fasting and after methionine loading in adolescents with
diabetic retinopathy and nephropathy.
J Pediatr. 2000;
137:386-392.
[PubMed: 10969265]
238. Kong A, Donath S, Harper CA, Werther GA, Cameron FJ. Rates
of diabetes mellitus-related complications in a contemporary adolescent cohort.
J
Pediatr Endocrinol Metab. 2005;18:247-255.
[PubMed: 15813603]
239. Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J. Declining
incidence of severe retinopathy and persisting decrease of nephropathy
in an unselected population of type 1 diabetesóthe Linkoping Diabetes
Complications Study.
Diabetologia. 2004;47:1266-1272.
[PubMed: 15235773]
240. Tight blood pressure control and risk of macrovascular
and microvascular complications in type 2 diabetes: UKPDS 38. UK
Prospective Diabetes Study Group. BMJ. 1998;317:703-713.
241. Dahlquist G, Rudberg S. The prevalence of microalbuminuria
in diabetic children and adolescents and its relation to puberty.
Acta
Paediatr Scand. 1987;76:795-800.
[PubMed: 3661181]
242. Joner G, Brinchmann-Hansen O, Torres CG, Hanssen KF. A
nationwide cross-sectional study of retinopathy and microalbuminuria
in young Norwegian type 1 (insulin-dependent) diabetic patients.
Diabetologia. 1992;35:1049-1054.
[PubMed: 1473614]
243. Mortensen HB, Marinelli K, Norgaard K, et al. A nationwide
cross-sectional study of urinary albumin excretion rate, arterial
blood pressure and blood glucose control in Danish children with
type 1 diabetes mellitus. Danish Study Group of Diabetes in Childhood.
Diabet
Med. 1990;7:887-897.
[PubMed: 2149686]
244. Mathiesen ER, Ronn B, Jensen T, Storm B, Deckert T. Relationship
between blood pressure and urinary albumin excretion in development
of microalbuminuria.
Diabetes. 1990;39:245-249.
[PubMed: 2227133]
245. Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of
captopril in postponing nephropathy in normotensive insulin dependent
diabetic patients with microalbuminuria.
BMJ. 1991;303:81-87.
[PubMed: 1860008]
246. Walker JD, Bending JJ, Dodds RA, et al. Restriction of
dietary protein and progression of renal failure in diabetic nephropathy.
Lancet. 1989;2:1411-1415.
[PubMed: 2574360]
247. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The
effect of dietary protein restriction on the progression of diabetic
and nondiabetic renal diseases: a meta-analysis.
Ann Intern
Med. 1996;124:627-632.
[PubMed: 8607590]
248. Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann
L, Berger M. Smoking is associated with progression of diabetic
nephropathy. Diabetes Care. 1994;17(2):126-131.
249. Kohner EM, Hamilton AM, Saunders SJ, Sutcliffe BA, Bulpitt
CJ. The retinal blood flow in diabetes.
Diabetologia. 1975;11:27-33.
[PubMed: 1140516]
250. Rosenbloom AL, Malone JI, Yucha J, Van Cader TC. Limited
joint mobility and diabetic retinopathy demonstrated by fluorescein
angiography.
Eur J Pediatr. 1984;141:163-164.
[PubMed: 6698062]
251. Lovestam-Adrian M, Agardh CD, Torffvit O, Agardh E. Diabetic
retinopathy, visual acuity, and medical risk indicators: a continuous
10-year follow-up study in type 1 diabetic patients under routine
care.
J Diabetes Complicat. 2001; 15:287-294.
[PubMed: 11711321]
252. Chaturvedi N, Sjoelie AK, Porta M, et al. Markers of insulin
resistance are strong risk factors for retinopathy incidence in
type 1 diabetes.
Diabetes Care. 2001;24:284-289.
[PubMed: 11213880]
253. Roy MS. Diabetic retinopathy in African Americans with
type 1 diabetes: the New Jersey 725: I. Methodology, population,
frequency of retinopathy, and visual impairment.
Arch Ophthalmol. 2000;118:97-104.
[PubMed: 10636422]
254. Maguire A, Chan A, Cusumano J, et al. The case for biennial
retinopathy screening in children and adolescents.
DiabetesCare. 2005;28:
509-513.
[PubMed: 15735179]
255. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of
lisinopril on progression of retinopathy in normotensive people
with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial
of Lisinopril in Insulin-Dependent Diabetes Mellitus.
Lancet. 1998;351:28-31.
[PubMed: 9433426]
256. Photocoagulation treatment of proliferative diabetic retinopathy:
the second report of diabetic retinopathy study findings. Ophthalmol. 1978;85:82-106.
257. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk
factors and diabetic neuropathy.
N Engl J Med. 2005;352:341-350.
[PubMed: 15673800]
258. Maser RE, Steenkiste AR, Dorman JS, et al. Epidemiological
correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology
of Diabetes Complications Study.
Diabetes. 1989;
38:1456-1461.
[PubMed: 2620781]
259 Kaar ML, Saukkonen AL, Pitkanen M, Akerblom HK. Peripheral
neuropathy in diabetic children and adolescents. A cross-sectional
study. Acta Paediatr Scand. 1983;72:373-378.
260. Starkman HS, Gleason RE, Rand LI, Miller DE, Soeldner JS.
Limited joint mobility (LJM) of the hand in patients with diabetes
mellitus: relation to chronic complications.
Ann Rheum Dis 1986;45:130-135.
[PubMed: 3947142]
261. White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane
WV. Beneficial effects of intensive therapy of diabetes during adolescence:
outcomes after the conclusion of the Diabetes Control and Complications
Trial (DCCT).
J Pediatr. 2001;139:804-812.
[PubMed: 11743505]
262. White NH, Waltman SR, Krupin T, Santiago JV. Reversal of
neuropathic and gastrointestinal complications related to diabetes
mellitus in adolescents with improved metabolic control.
J
Pediatr. 1981;99:41-45.
[PubMed: 7019402]
263. Reid B, DiLorenzo C, Travis L, Flores AF, Grill BB, Hyman
PE. Diabetic gastroparesis due to postprandial antral hypomotility
in childhood. Pediatrics. 1992;90(1 Pt 1):43-46.
264. Maser RE, Lenhard MJ. Cardiovascular autonomic neuropathy
due to diabetes mellitus: clinical manifestations, consequences,
and treatment.
J Clin Endocrinol Metab. 2005;90:5896-5903.
[PubMed: 16014401]
265. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from
heart disease in a cohort of 23,000 patients with insulin-treated
diabetes.
Diabetologia. 2003; 46:760-765.
[PubMed: 12774166]
266. Laing SP, Swerdlow AJ, Slater SD, et al. The British Diabetic
Association Cohort Study, I: all-cause mortality in patients with
insulin-treated diabetes mellitus.
Diabet Med. 1999;16:
459-465.
[PubMed: 10391392]
267. Jarvisalo MJ, Raitakari M, Toikka JO, et al. Endothelial
dysfunction and increased arterial intima-media thickness in children
with type 1 diabetes.
Circulation. 2004;109:1750-1755.
[PubMed: 15023875]
268. Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude
and determinants of coronary artery disease in juvenile-onset, insulin-dependent
diabetes mellitus.
Am J Cardiol. 1987;59:750-755.
[PubMed: 3825934]
269. Dahl-Jorgensen K, Larsen JR, Hanssen KF. Atherosclerosis
in childhood and adolescent type 1 diabetes: early disease, early
treatment?
Diabetologia. 2005;48:1445-1453.
[PubMed: 15971059]
270. McGill HC Jr, McMahan CA. Determinants of atherosclerosis
in the young. Pathobiological Determinants of Atherosclerosis in
Youth (PDAY) Research Group. Am J Cardiol. 1998;8
2:30T-36T.
271. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy
RE, Wattigney WA. Association between multiple cardiovascular risk
factors and atherosclerosis in children and young adults. The Bogalusa
Heart Study.
N Engl J Med. 1998;338:1650-1656.
[PubMed: 9614255]
272. Haller MJ, Samyn M, Nichols WW, et al. Radial artery tonometry
demonstrates arterial stiffness in children with type 1 diabetes.
Diabetes
Care. 2004;27:2911-2917.
[PubMed: 15562206]
273. Ceriello A. Endothelial cell dysfunction. International
Diabetes Monitor. 2005;17:8-15.
274. Sarman B, Farkas K, Toth M, Somogyi A, Tulassay Z. Circulating
plasma endothelin-1, plasma lipids and complications in type 1 diabetes
mellitus.
Diabetes Nutr Metab. 2000;13:142-148.
[PubMed: 10963390]
275. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting
enzyme inhibitor, ramipril, on cardiovascular events in high-risk
patients. The Heart Outcomes Prevention Evaluation Study Investigators.
N
Engl J Med. 2000;342:145-153.
[PubMed: 10639539]
276. Bauriedel G, Skowasch D, Schneider M, Andrie R, Jabs A,
Luderitz B. Antiplatelet effects of angiotensin-converting enzyme
inhibitors compared with aspirin and
clopidogrel: a pilot study
with whole-blood aggregometry.
Am Heart J. 2003;145(2):343-8.
277. Nathan DM, Cleary PA, Backlund JY, et al. Diabetes Control
and Complications Trial/Epidemiology of Diabetes Interventions
and Complications (DCCT/EDIC) Study Research Group: intensive diabetes
treatment and cardiovascular disease in patients with type 1 diabetes.
N
Engl J Med. 2005;353:2643–2653.
[PubMed: 16371630]
278. American Diabetes Association. Standards of medical care
in diabetes. Diabetes Care. 2005;28 (suppl 1):S4-S36.
279. Ong HT. The statin studies: from targeting hypercholesterolaemia
to targeting the high-risk patient.
QJM. 2005;98:599-614.
[PubMed: 16006501]
280. Donaghue KC, Chiarelli F, Trotta D, Allgrove J, hl-Jorgensen
K. ISPAD Clinical Practice Consensus Guildelines 2006-2007. Microvascular
and macrovascular complications.
PediatrDiabetes. 2007;8:163-170.
[PubMed: 17550427]
281. McCrindle BW, Helden E, Cullen-Dean G, Conner WT. A randomized
crossover trial of combination pharmacologic therapy in children
with familial hyperlipidemia.
Pediatr Res. 2002;51:715-721.
[PubMed: 12032266]
282. Adler AI, Stratton IM, Neil HA, et al. Association of systolic
blood pressure with macrovascular and microvascular complications
of type 2 diabetes (UKPDS 36): prospective observational study.
BMJ. 2000;321:412-419.
[PubMed: 10938049]
283. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of
intensive blood-pressure lowering and low-dose aspirin in patients
with hypertension: principal results of the Hypertension Optimal Treatment
(HOT) randomised trial. HOT Study Group.
Lancet. 1998;351:1755-1762.
[PubMed: 9635947]
284. Rosenbloom AL, Joe JR, Young RS, Winter WE. The emerging
epidemic of type 2 diabetes mellitus in youth.
Diabetes
Care. 1999;22:345-354.
[PubMed: 10333956]
285. Duncan GE. Prevalence of diabetes and impaired fasting
glucose levels among US adolescents: National Health and Nutrition
Examination Survey, 1999-2002. Arch Pediatr Adolesc Med. 2006;1
60:523-528.
286. Pinhas-Hamiel O, Dolan LM, Daniels SR, et al. Increased
incidence of non-insulin-dependent diabetes mellitus among adolescents.
J
Pediatr. 1996;128:608-615.
[PubMed: 8627431]
287. Drake AJ, Smith A, Betts PR, Crowne EC, Shield JP. Type
2 diabetes in obese white children.
Arch Dis Child. 2002;86:207-208.
[PubMed: 11861246]
288. Kitagawa T, Owada M, Urakami T, Yamauchi K. Increased incidence
of non-insulin dependent diabetes mellitus among Japanese schoolchildren correlates
with an increased intake of animal protein and fat.
Clin
Pediatr. 1998;37:111-115.
[PubMed: 9492119]
289. Ehtisham S, Barrett TG, Shawl NJ. Type 2 diabetes mellitus
in UK childrenóan emerging problem.
Diabetic Med. 2000;17:867-871.
[PubMed: 11168330]
290. The Writing Group for the SEARCH for Diabetes in Youth
Study Group. Incidence of diabetes in youth in the United States. JAMA. 2007;297:2716-2724.
291. Savage PJ, Bennett PH, Senter RG, Miller M. High prevalence
of diabetes in young Pima Indians.
Diabetes. 1979;28:937-942.
[PubMed: 478185]
292. Dabelea D, Hanson RL, Bennett PH, et al. Increasing prevalence
of type 2 diabetes in American Indian children.
Diabetologia. 1998;41:904-910.
[PubMed: 9726592]
293. Dean HJ. NIDDM-Y in First Nation children in Canada. Clin
Pediatr. 1998;39:89-96.
294. Neufeld ND, Raffal LF, Landon C, et al. Early presentation
of type 2 diabetes in Mexican-American youth.
Diabetes Care. 1998;21:80-86.
[PubMed: 9538974]
295. Kadiki OA, Reddy MR, Marzouk AA. Incidence of insulin-dependent
diabetes (IDDM) and non-insulin-dependent diabetes (NIDDM) (0-34 years
at onset) in Benghazi, Libya.
Diabetes Res Clin Pract. 1996;32:165-173.
[PubMed: 8858205]
296. Chan JCN, Cheung CK, Swaminathan R, et al. Obesity, albuminuria,
and hypertension among Hong Kong Chinese with non-insulin-dependent diabetes
mellitus (NIDDM).
Postgrad Med J. 1993;69:204-210.
[PubMed: 8497435]
297. Kitagawa T, Owada M, Urakami T, Yamauchi K. Increased incidence
of non-insulin dependent diabetes mellitus among Japanese schoolchildren
correlates with an increased intake of animal protein and fat.
Clin
Pediatr. 1998; 37:111-115.
[PubMed: 9492119]
298. Sayeed MA, Hussain MZ, Banu A, et al. Prevalence of diabetes
in a suburban population of Bangladesh.
Diabetes Res Clin
Pract. 1997;34:149-155.
[PubMed: 9069566]
299. Braun B, Zimmerman MB, Kretchmer N, et al. Risk factors
for diabetes and cardiovascular disease in young Australian aborigines.
A 5-year follow-up study.
Diabetes Care. 1996;19:472-479.
[PubMed: 8732712]
300. McGrath NM, Parker GN, Dawson P. Early presentation of
type 2 diabetes mellitus in young New Zealand Maori
.Diabetes
Res Clin Pract. 1999;43:205-209.
[PubMed: 10369431]
301. Pinhas-Hamiel O, Zeitler P. The global spread of type 2
diabetes mellitus in children and adolescents.
J Pediatr. 2005;146:693-700.
[PubMed: 15870677]
302. Botero D, Woldsorf JI. Diabetes mellitus in children and
adolescents.
Arch Med Res. 2005; 36:281-290.
[PubMed: 15925018]
303. Decsi T, Molnar D. Insulin resistance syndrome in children:
pathophysiology and potential management strategies.
Paediatr
Drugs. 2003;5:291-299.
[PubMed: 12716216]
304. Weiss R, Dufour S, Taksali SE, et al. Prediabetes in obese
youth: a syndrome of impaired glucose tolerance, severe insulin
resistance, and altered myocellular and abdominal fat partitioning.
Lancet. 2003;362:951-957.
[PubMed: 14511928]
305. Knowles HC. Diabetes mellitus in childhood and adolescence.
Med
Clin North Am. 1971;55:975-987.
[PubMed: 4946764]
306. Pihoker C, Scott CR, Lensing SY, Cradock MM, Smith J. Non-insulin
dependent diabetes mellitus in African-American youths of Arkansas.
ClinPediatr. 1998;37:97-102.
[PubMed: 9492117]
307. Rosenbloom AL, Joe JR, Young RS, Winter WE. The emerging
epidemic of type 2 diabetes mellitus in youth.
DiabetesCare. 1999;22:345-354.
[PubMed: 10333956]
309. Upchurch, SL, Brosnan CA, Meininger, JC, Wright, DE, Campbell
JA, McKay SV, Schreiner B. Characteristics of 98 children and adolescents diagnosed
with type 2 diabetes by their health care provider at initial presentation.
DiabetesCare. 2003;26:
2209.
[PubMed: 12832339]
310. Glaser NS, Jones KL. Non-insulin-dependent diabetes mellitus
in Mexican-American children.
West J Med. 1998;168:11-16.
[PubMed: 9448482]
311. Neufeld ND, Raffal LF, Landon C, Chen Y-DI, Vadheim CM.
Early presentation of type 2 diabetes in Mexican-American youth.
DiabetesCare. 1998;21:80-86.
[PubMed: 9538974]
312. Dabelea D, Hanson RL, Bennett PH, Roumain J, Knowler WC,
Pettitt DJ. Increasing prevalence of type 2 diabetes in American
Indian children.
Diabetologia. 1998;41:904-910.
[PubMed: 9726592]
313. Dean HJ. NIDDM-Y in First Nation children in Canada. Clin
Pediatr. 39:89-96, 1998.
314. Pinhas-Hamiel O, Zeitler P. The global spread of type 2
diabetes mellitus in children and adolescents.
J Pediatr. 2005;146:693-700.
[PubMed: 15870677]
315. Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type
2 diabetes among North American children and adolescents: an epidemiological
review and a public health perspective.
JPediat. 2000;136:664-672.
[PubMed: 10802501]
316. Drake AJ, Smith A, Betts PR, Crowne EC, Shield JP. Type
2 diabetes in obese white children.
Arch Dis Child. 2002;86:207-208.
[PubMed: 11861246]
317. Troiano RP, Flegal KM. Overweight children and adolescents:
description, epidemiology, and demographics.
Pediatrics. 1998;101:497-504.
[PubMed: 12224656]
318. Freedman DS, Srinivasan SR, Valdez RA, Williamson DF, Berenson
GS. Secular increases in relative weight and obesity among children
over two decades: The Bogalusa Heart Study.
Pediatrics. 1997;99:420-426.
[PubMed: 9041299]
319. Strauss RS, Pollack HA. Epidemic increase in childhood
overweight, 1986-1998.
JAMA. 2001;286:2845-2848.
[PubMed: 11735760]
320. Livingstone B. Epidemiology of childhood obesity in Europe. Eur
J Pediatr. 2000;159:(suppl 1):S14-S34.
321. Wang Y. Cross-national comparison of childhood obesity:
the epidemic and the relationship between obesity and socioeconomic
status.
Int J Epidemiol. 2001;30:1129-1136.
[PubMed: 11689534]
322. Cheng TO. Childhood obesity in China.
Health and
Place. 2004;10:395-396.
[PubMed: 15491898]
323. Yanovski SZ, Yanovski JA. Obesity.
N Engl J Med. 2002;346:591-602.
[PubMed: 11856799]
324. Blair SN, Nichaman MZ. The public health problem of increasing
prevalence rates of obesity and what should be done about it.
Mayo
Clin Proc. 2002;77:109-113.
[PubMed: 11838643]
325. Neel JV. Diabetes mellitus: a “thrifty” genotype
rendered detrimental by “progress”?
Am
J Hum Genet. 1962;14:353-362.
[PubMed: 13937884]
326. Lev-Ran A. Thrifty genotype: how applicable is it to obesity
and type 2 diabetes? Diabetes Reviews. 1999;7:1-22.
327. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance
and insulin secretory dysfunction as precursors of non-insulin-dependent
diabetes mellitus: prospective studies of Pima Indians.
N
Engl J Med. 1993;329:1988-1992.
[PubMed: 8247074]
328. Haffner SM, Stern MP, Dunn J, Mobley M, Blackwell J, Bergman
RN. Diminished insulin sensitivity and increased insulin response
in non-obese, non-diabetic Mexican Americans.
Metabolism. 1990;39:842-847.
[PubMed: 2198435]
329. Haffner SM, Miettinen H, Stern MP. Insulin secretion and
resistance in nondiabetic Mexican Americans and non-Hispanic whites
with a parental history of diabetes.
J Clin Endocrinol Metab. 1996;81:1846-1851.
[PubMed: 8626845]
330. Groop L, Forsblom C, Lehtovirta M, et al. Metabolic consequences
of a family history of NIDDM (the Botnia Study): evidence for sex specific
parental effects.
Diabetes. 1996;45:1585-1593.
[PubMed: 8866565]
331. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner
JS, Kahn CR. Role of glucose and insulin resistance in development
of type 2 diabetes mellitus: results of a 25 year follow-up study.
Lancet. 1992;340:925-929.
[PubMed: 1357346]
332. Pigon J, Giacca A, Ostenson C-G, Lam L, Vranic M, Efendi
S. Normal hepatic insulin sensitivity in lean, mild non-insulin-dependent
diabetic patients.
J Clin Endocrinol Metab. 1996;81:3702-3708.
[PubMed: 8855826]
333. O’Rahilly S, Turner RC, Matthew D. Impaired pulsatile
secretion of insulin in relatives of patients with non-insulin-dependent
diabetes.
N Engl J Med. 1988;318:1225-1230.
[PubMed: 3283553]
334. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment
of insulin resistance and type II diabetes. Diabetes. 1994;45:1661-1669.
335. Philipps K, Barker DJP. Fetal growth and impaired glucose
tolerance in men and women. Diabetologia. 1993;36:225-228.
336. Phillips DIW, Barker DJP, Hales CN, Hirst S, Osmond C.
Thinness at birth and insulin resistance in adult life.
Diabetologia. 1994;37:150-154.
[PubMed: 8163048]
337. Lithell HO, McKeigue PM, Berglund L, Mohsen R, Lithell
UB, Leon DA. Relation at birth to non-insulin-dependent diabetes
and insulin concentrations in men aged 50-60 years.
Brit
Med J. 1996; 312:406-410.
[PubMed: 8601111]
338. Curhan GC, Willett WC, Rimm EB, Spiegelman D, Ascherio
AL, Stampfer MJ. Birth weight and adult hypertension, diabetes mellitus,
and obesity in US men.
Circulation. 1996;94:3246-3250.
[PubMed: 8989136]
339. Ravelli AC, van der Meulen JH, Michels RP, et al. Glucose
tolerance in adults after prenatal exposure to famine.
Lancet. 1998;351:173-177.
[PubMed: 9449872]
340. Levitt NS, Lambert EV, Woods D, Hales CN, Andrew R, Seckl
JR. Impaired glucose tolerance and elevated blood pressure in low
birth weight, nonobese, young South African adults: early programming
of cortisol axis.
J Clin Endocrinol Metab. 2000;85:4611-4618.
[PubMed: 11134116]
341. Dabelea D, Pettitt DJ, Hanson RL, Imperatore G, Bennett
PH, Knowler WC. Birthweight, type 2 diabetes, and insulin resistance
in Pima Indian children and young adults.
Diabetes Care. 1999;22:944-950.
[PubMed: 10372247]
342. Bavdekar A, Yajnik CS, Fall CHD, et al. Insulin resistance
syndrome in 8-year old Indian children. Small at birth, big at 8
years, or both?
Diabetes. 1999;48:2422-2429.
[PubMed: 10580432]
343. Li C, Johnson MS, Goran MI. Effects of low birth weight
on insulin resistance syndrome in Caucasian and African-American
children.
Diabetes Care. 2001;24:2035-2042.
[PubMed: 11723079]
344. Koletzko B, Broekaert I, Demmelmair H, et al. Protein intake
in the first year of life: a risk factor for later obesity? The
EU childhood obesity project.
Adv Exp Med Biol. 2005;569:69-79.
[PubMed: 16137110]
345. Pettitt DJ, Forman MR, Hanson RL, Knowler WC, Bennett PH.
Breastfeeding and incidence of non-insulin-dependent diabetes mellitus
in Pima Indians.
Lancet. 1997;350:166-168.
[PubMed: 9250183]
346. Von Kries R, Koletzko R, Sauerwald T, et al. Breast feeding
and obesity: cross-sectional study. BMJ. 1999;319:147-150.
347. Plagemann A. A matter of insulin: Developmental programming
of body weight regulation.
J Matern Fetal Neonatal Med. 2008;21:143-148.
[PubMed: 18297568]
348. Dunger DB, Ong KK, Huxtable SJ, et al. Association of the
INS VNTR with size at birth. ALSPAC study team. Avon longitudinal
study of pregnancy and childhood.
Nat Genet. 1998;19:98-100.
[PubMed: 9590300]
349. Hattersley AT, Beards F, Ballantyne E, Appleton M, Harvey
R, Ellard S. Mutations in the glucokinase gene of the fetus result
in reduced birthweight.
Nat Genet. 1998;19:268-270.
[PubMed: 9662401]
350. Jaquet D, Vidal H, Hankard R, Czernichow P, Levy-Marchal
C. Impaired regulation of glucose transporter 4 gene expression
in insulin resistance associated with in utero undernutrition.
J
ClinEndocrinol Metab. 2001;86:3266-3267.
[PubMed: 11443199]
351. Pettitt DJ, Aleck KA, Baird HR, Carraher MJ, Bennett PH,
Knowler WC. Congenital susceptibility to NIDDM: role of intrauterine
environment.
Diabetes. 1988;37:622-628.
[PubMed: 3360218]
352. Silverman BL, Metzger BE, Cho NH, Loeb CA. Impaired glucose
tolerance in adolescent offspring of diabetic mothers. Relationship
to fetal hyperinsulinism.
Diabetes Care. 1995;18:611-617.
[PubMed: 8585997]
353. Hillier TA, Pedula KL, Schmidt MM. Childhood obesity and
metabolic imprinting: the ongoing effects of maternal hyperglycemia.
Diabetes
Care. 2007;30:2287-2292
[PubMed: 17519427]
354. Dabelea D, Knowler WC, Pettitt DJ. Effect of diabetes in
pregnancy on offspring: follow-up research in the Pima Indians.
J
Matern Fetal Med. 2000;9:83-88.
[PubMed: 10757442]
355. Rosenbloom AL, Wheeler L, Bianchi R, Chin FT, Tiwary CM,
Grgic A. Age adjusted analysis of insulin responses during normal
and abnormal oral glucose tolerance tests in children and adolescents.
Diabetes. 1975;24:820-828.
[PubMed: 1158042]
356. Caprio S, Tamborlane WV. Metabolic impact of obesity in
childhood.
Endocrinol Metab ClinNorth
Am. 1999;28:731-747.
[PubMed: 10609117]
357. Caprio S. Relationship between abdominal visceral fat and
metabolic risk factors in obese adolescents.
Am J Hum Biol. 1999;11:259-266.
[PubMed: 11533949]
358. Mohan V, Jaydip R, Deepa R. Type 2 diabetes in Asian Indian
youth. Pediatr Diabetes. 2007;8 (suppl 9):28-34.
359. Drash AM. Relationship between diabetes mellitus and obesity
in the child.
Metabolism. 1973;22: 337-344.
[PubMed: 4687958]
360. Martin MM, Martin AL. Obesity, hyperinsulinism, and diabetes
mellitus in childhood.
J Pediatr. 1973;82:192-201.
[PubMed: 4684363]
361. Young-Hyman D, Schlundt DG, Herman L, DeLuca F, Counts
D. Evaluation of the insulin resistance syndrome and 5- to 10-year
old overweight/obesity African-American children.
Diabetes
Care. 2001;24:1359-1364.
[PubMed: 11473070]
362. Svec F, Nastasi K, Hilton C, Bao W, Srinivasan SR, Berenson
GS. Black-white contrasts and insulin levels during pubertal development:
the Bogalusa Heart Study.
Diabetes. 1992;41:313-317.
[PubMed: 1551490]
363. Jiang X, Srinivasan SR, Radhakrishnamurthy B, Dalferes
ER, Berenson GS. Racial (black-white) differences in insulin secretion
and clearance in adolescents: the Bogalusa heart study.
Pediatrics. 1996;97:357-360.
[PubMed: 8604270]
364. Arslanian S. Insulin secretion and sensitivity in healthy
African-American vs. American-white children.
Clin Pediatr. 1998;37:81-88.
[PubMed: 9492115]
365. Danadian K, Lewy V, Janosky JJ, Arslanian S. Lipolysis
in African-American children: is it a metabolic risk factor predisposing
to obesity?
J Clin Endocrinol Metab. 2001;86:3022-3026.
[PubMed: 11443162]
366. Writing group for the SEARCH for diabetes in youth study
group. Incidence of diabetes in youth in United States. JAMA. 2007;297:2760-2762.
367. Webster-Gandy J, Warren J, Henry CJ. Sexual dimorphism
in fat patterning in a sample of 5 to 7-year-old children in Oxford.
Int
J Food Sci Nutr. 2003;54:467-471.
[PubMed: 14522692]
368. Danadian K, Balasekaran G, Lewy V, Meza MP, Robertson R,
Arslanian SA. Insulin sensitivity in African-American children with
and without a family history of type 2 diabetes.
Diabetes
Care. 1999;22:1325-1329.
[PubMed: 10480778]
369. Hanis CL, Boerwinkle E, Chakraborty R, et al. A genome-wide
search for human non-insulin-dependent (type 2) diabetes genes reveals
a major susceptibility locus on chromosome 2.
Nat Genet. 1996;13:161-166.
[PubMed: 8640221]
370. Lindgren CM, Hirschhorn JN. The genetics of type 2 diabetes. The
Endocrinologist. 2001;11:178-187.
371. Horikawa Y, Oda N, Cox NJ, et al. Genetic variation in
the gene encoding calpain-IO is associated with type 2 diabetes
mellitus.
Nat Genet. 2000;26:163-175.
[PubMed: 11017071]
372. Baier LJ, Permana PA, Yang X, et al. A calpain 10 gene
polymorphism is associated with reduced muscle mRNA levels and insulin
resistance. J Clin Invest. 2000;106:R69-R73.
373. American Diabetes Association Consensus Development Conference
on Insulin Resistance. Diabetes Care. 1998;21:310-314.
374. Rosenbloom AL. Hyperglycemic crises and their complications
in children.
J Ped Endocrinol Metab. 2007;20:5-18.
[PubMed: 17315523]
375. Pinhas-Hamiel O, Zeitler P. Acute and chronic complications
of type 2 diabetes mellitus in children and adolescents.
Lancet. 2007;369:1823-1831.
[PubMed: 17531891]
376. Freedman DS, Khan LK, Dietz WH, Srinivasan SR, Berenson
GS. Relationship of childhood obesity to coronary heart disease
risk factors in adulthood: the Bogalusa heart study.
Pediatrics. 2001;108:712-718.
[PubMed: 11533341]
377. Berenson GS, Srnivasan SR. Cardiovascular risk factors
in youth with implications for aging: the Bogalusa Heart Study.
Neurobiol
Aging. 2005;26:303-307.
[PubMed: 15639307]
378. Juonala M, Jarvisalo MJ, Maki-Torkko N, Kahonen M, Viikari
JS, Raitakari OT. Risk factors identified in childhood and decreased
carotid artery elasticity in adulthood: the Cardiovascular Risk
in Young Finns Study.
Circulation. 2005;112:1486-1493.
[PubMed: 16129802]
379. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB.
Low-grade systemic inflammation in overweight children. Pediatrics. 2001;107:e13.
380. Adelman RD, Restaino IG, Alon US, Blowey DL. Proteinuria
and focal segmental glomerulosclerosis in severely obese adolescents.
J
Pediatr. 2001;138:481-485.
[PubMed: 11295709]
381. Smith JC, Field C, Braden DS, Gaymes CH, Kastner J. Coexisting
health problems inobese children and adolescents that might require
special treatment considerations.
Clin Pediatr. 1999;38:305-307.
[PubMed: 10349530]
382. Strauss RS, Barlow SE, Dietz WH. Prevalence of abnormal
serum amrinotransferase values in overweight and obese adolescents.
J
Pediatr. 2000;136:727-733.
[PubMed: 10839867]
383. Kirpichnikov D, Sowers JR. Diabetes mellitus and diabetes-associated
vascular disease.
TrendsEndocrinolMetab. 2001;12:225-230.
[PubMed: 11397648]
384. Laakso, M. Lipids in type 2 diabetes.
Semin Vasc
Med. 2002;2:59-66.
[PubMed: 16222596]
385. Goldberg IJ. Diabetic dyslipidemia: causes and consequences.
J
Clin Endocrinol Metab. 2001;86: 965-971.
[PubMed: 11238470]
386. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL.
Hypertension and antihypertensive therapy has risk factors for type
2 diabetes mellitus. Atherosclerosis Risk in Community Study.
N
Engl J Med. 2000;342:905-912.
[PubMed: 10738048]
387. Salomaa VV, Strandberg TE, Vanhanen H, Naukkarinen V, Sarna
S, Miettinen TA. Glucose tolerance and blood pressure: long-term
follow-up in middle-age men.
BMJ. 1991;302:493-496.
[PubMed: 2012844]
388. Wierzbicki AS, Nimmo L, Feher MD, Cox A, Foxton J, Lant
AF. Association of angiotensinconverting enzyme DD genotype with
hypertension in diabetes.
J Hum Hypertens. 1995;9:671-673.
[PubMed: 8523387]
389. Poredos P. Endothelial dysfunction and cardiovascular disease.
Pathophysiol
Haemost Thromb. 2002;32:274-277.
[PubMed: 13679656]
390. Tounian P, Aggoun Y, Dubern B, et al. Presence of increased
stiffness of the common carotid artery and endothelial dysfunction
in severely obese children: a prospective study.
Lancet. 2001;358:1400-1404.
[PubMed: 11705484]
391. Aldhahi W, Hamdy O. Adipokines, inflammation, and the endothelium
in diabetes.
Curr Diab Rep. 2003;3:293-298.
[PubMed: 12866991]
392. You T, Yang R, Lyles MF, Gong D, Nicklas BJ. Abdominal
adipose tissue cytokine gene expression: relationship to obesity
and metabolic risk factors. Am J Physiol Endocrinol Metab.
2005;288:E741-E747.
393. Shimabukuro M, Higa N, Asahi T, et al. Hypoadiponectinemia
is closely linked to endothelial dysfunction in man.
J Clin
Endocrinol Metab. 2003;88:3236-3240.
[PubMed: 12843170]
394. Stuart CA, Gilkison CR, Smith MM, Bosma AM, Keenan BS,
Nagamani M. Acanthosis nigricans as a risk factor for non-insulin
dependent diabetes mellitus.
Clin Pediatr. 1998;37:73-79.
[PubMed: 9492114]
395. Nguyen TT, Keil MF, Russell DL, et al. Relation of acanthosis
nigricans to hyperinsulinemia and insulin sensitivity in overweight
African-American and white children.
J Pediatr. 2001;138:474-480.
[PubMed: 11295708]
396. Sackett DL, Holland WW. Controversy in detection of disease. Lancet.
1965;ii:357-359.
397. Tirosh A, Shai I, Tekes-Manova D, et al., for the Israeli
Diabetes Research Group. Normal fasting plasma glucose levels and
type 2 diabetes in young men.
N Engl J Med. 2005;353:1454-1462.
[PubMed: 16207847]
398. Sokol RJ. The chronic disease of childhood obesity: the
sleeping giant has awakened.
J Pediatr. 2000;136:711-713.
[PubMed: 10905886]
399. Tersbakovec AM, Watson MH, Wenner WJ, Marx AL. Insurance
reimbursement for treatment of obesity in children. J Pediatr. 1999;134:573-578.
400. Zwiaur KFM. Prevention and treatment of overweight and
obesity in children and adolescents. Eur J Pediatr. 2000;159(suppl
1):S56-S68.
401. Segel DG, Sanchez JC. Childhood obesity in the year 2001. The
Endocrinologist. 2001;11:296-306.
402. Trevino RP, Pugh JA, Hernadez AE, Menchaca VD, Ramirez
RR, Mendoza M. Bienestar: a diabetes risk factor prevention program.
J
Sch Health. 1998;68:62-66.
[PubMed: 9571575]
403. Epstein LH, Myers MD, Raynor HA, Saelens BE. Treatment
of pediatric obesity.
Pediatrics. 1998;101:554-570.
[PubMed: 12224662]
404. Cook VV, Hurley JS. Prevention of type 2 diabetes in childhood.
Clin
Pediatr. 1998;37:123-129.
[PubMed: 9492121]
405. Teufel NI, Ritenbaugh CK. Development of a primary prevention
program: insight gained in the Zuni Diabetes Prevention Program.
Clin
Pediat. 1998;37:131-141.
[PubMed: 9492122]
406. Gortmaker SL, Cheung LWY, Peterson KE, et al. Impact of
a school-based interdisciplinary intervention on diet and physical
activity among urban primary school children.
Arch PediatrAdolesc
Med. 1999;153:975-983.
[PubMed: 10482216]
407. Macaulay AC, Paradis G, Potvin L, et al. The Kahnawake
Schools Diabetes Prevention Project: intervention, evaluation and
baseline results of a diabetes primary prevention program with a
native community in Canada.
Prev Med. 1997;26:779-790.
[PubMed: 9388789]
408. Perry CL, Stone EJ, Parcel GS, et al. School-based cardiovascular
health promotion: the child and adolescents trial for cardiovascular
health (CATCH). J Sch Health. 1998;68:406-413.
409. Savoye M, Shaw M, Dziura WV, et al. Effects of the weight
management program on body composition and metabolic parameters
in overweight children: a randomized controlled trial.
JAMA. 2007;297:2697-2704.
[PubMed: 17595270]
410. Jakicic JM. Exercise in the treatment of obesity.
Endocrinol
Metab Clin North Am. 2003;32:967-980.
[PubMed: 14711070]
411. Vestfold Heartcare Study Group. Influence on lifestyle
measures and five-year coronary risk by a comprehensive lifestyle
intervention programme in patients with coronary heart disease. J
Cardiovasc Risk. 2003;10:429-437.
412. Moyna NM, Thompson PD. The effect of physical activity
on endothelial function in man.
Acta Physiol Scand. 2004;180:113-123.
[PubMed: 14738470]
413. Ishikawa-Takata K, Ohta T, Tanaka H. How much exercise
is required to reduce blood pressure in essential hypertensives:
a dose-response study.
Am J Hypertens. 2003;16:629-633.
[PubMed: 12878367]
414. Cummings S, Parham ES, Strain GW. Position of the American
Dietetic Association: weight management.
J Am Diet Assoc. 2002;102:1145-1155.
[PubMed: 12171464]
415. Zabinski MF, Saelens BE, Stein RI, Hayden-Wade HA, Wilfley
DE. Overweight children’s barriers to and support for physical
activity.
Obes Res. 2003;11:238-246.
[PubMed: 12582220]
416. Baird J, Fisher D, Lucas P, Kleijnen J, Roberts H, Law
C. Being big or growing fast: systematic review of size and growth
in infancy and later obesity.
BMJ. 2005;331:929.
[PubMed: 16227306]
417. Levine MD, Ringham RM, Kalarchian MA, Wisniewski L, Marcus
MD. Is family based behavioral weight control appropriate for severe
pediatric obesity?
Int J Eat Disord. 2001;30:318-328.
[PubMed: 11746293]
418. Robinson TM. Reducing children’s television viewing
to prevent obesity. A randomized controlled trial. JAMA. 1999;82:1561-1567.
419. Swinburn BA, Metcalf PA, Ley SJ. Long-term (five-year)
effects of a reduced fat diet intervention in individuals with glucose
intolerance.
Diabetes Care. 2001;24: 619-624.
[PubMed: 11315819]
420. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention
of type 2 diabetes mellitus by changes in lifestyle among subjects
with impaired glucose tolerance.
N Engl J Med. 2001;344:1343-1350.
[PubMed: 11333990]
421. Diabetes Prevention Program Research Group. Reduction in
the incidence of type 2 diabetes with lifestyle intervention or
metformin. N Engl J Med. 2002;346:393-403.
422. Jeffrey RW. Community programs for obesity prevention:
The Minnesota Heart Health Program. ObesityRes. 1995;3(suppl
2):283S-288S.
423. Epstein LH, Valoski AM, Kalarchian MA, McCurley J. Do children
lose and maintain weight easier than adults: a comparison of child
and parent weight changes from six months to ten years.
ObesRes. 1995;3:411-417.
[PubMed: 8521160]
424. Joe JR: Perceptions of diabetes by Indian adolescents.
In: Joe JR, Young RS, eds. Diabetes as a Disease of Civilization:
the Impact of Culture Change on Indigenous Peoples. Berlin:
Mouton de Gruyter; 1994:329-356.
425. Miller WC. How effective are traditional dietary and exercise
interventions for weight loss?
Med Sci Sports Exerc. 1999;31:1129-1134.
[PubMed: 10449014]
426. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J.
Effect of orlistat on weight and body composition in obese adolescents:
a randomized controlled trial.
JAMA. 2005;293:2873-2883.
[PubMed: 15956632]
427. Freemark M, Bursey D. The effects of metformin on body
mass index and glucose tolerance in obese adolescents with fasting
hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001;107(4):
E55.
428. Leung WY, Neil Thomas G, Chan JC, Tomlinson B. Weight management
and current options in pharmacotherapy: orlistat and sibutramine.
Clin
Ther. 2003;25:58-80.
[PubMed: 12637112]
429. Thearle M, Aronne LJ. Obesity and pharmacologic therapy.
Endocrinol
Metab Clin North Am. 2003;32:1005-1024.
[PubMed: 14711072]
430. Bray GA, Hollander P, Klein S, et al. A 6-month randomized,
placebo-controlled, dose-ranging trial of
topiramate for weight
loss in obesity.
Obes Res. 2003;11:722-733.
[PubMed: 12805393]
431. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of
food intake in obese subjects by peptide YY3-36.
N Engl
J Med. 2003;349:941-948.
[PubMed: 12954742]
432. Esposito K, Giugliano D. Effect of rimonabant on weight
reduction and cardiovascular risk.
Lancet. 2005;366:367-368;
author reply 369-370.
[PubMed: 16054931]
433. Huerta MG, Roemmich JN, Kington ML, et al. Magnesium deficiency
is associated with insulin resistance in obese children.
Diabetes
Care. 2005;28:1175-1181.
[PubMed: 15855585]
434. Inge TH, Zeller M, Garcia VF, Daniels SR. Surgical approach
to adolescent obesity.
AdolescMedClin. 2004;15:429-453.
[PubMed: 15625986]
435. Sjostrom L, Narbro K, Sjostrom D, et al. Effects of bariatric
surgery on mortality in Swedish obese subjects.
N Engl J
Med. 2007;357:741-752.
[PubMed: 17715408]
436. Dixon JB, O’Brien PE, Playfair J, et al. Adjustable
gastric banding and conventional therapy for type 2 diabetes.
JAMA. 2008;299:316-323.
[PubMed: 18212316]
437. Fagot-Compagna A, Knowler WC, Pettitt DJ. Type 2 diabetes
in Pima Indian Children: cardiovascular risk factors at diagnosis
and 10 years later. Diabetes. 1998;(suppl 1):A155.
438. Yokoyama H, Okudaira M, Otani T, et al. High incidence
of diabetic nephropathy in early-onset Japanese NIDDM patients.
Risk analysis.
Diabetes Care. 1998;21:1080-1085.
[PubMed: 9653599]
439. UKPDS Group: intensive blood glucose control with sulphonylureas
or insulin compared with conventional treatment and risk of complications
in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837-853.
440. UKPDS Group. Tight blood pressure control and risk of macrovascular
and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
441. Ludwig DS, Peterson KE, Gortmaker SL. Relation between
consumption of sugar sweetened drinks and childhood obesity: a prospective
observational analysis.
Lancet. 2001;357:505-508.
[PubMed: 11229668]
442. Willi SM, Martin K, Datko FM, Brant BP. Treatment of type
2 diabetes in childhood using a very-low-calorie diet. Diabetes
Care. 2004;227:348-353.
443. DeFronzo RA, Goodman AM. Efficacy of metformin in patients
with non-insulin dependent diabetes mellitus. The multicenter metformin
study group.
N Engl J Med. 1995;333:541-549.
[PubMed: 7623902]
444. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson
MJ. Effect of metformin in pediatric patients with type 2 diabetes:
a randomized controlled trial.
Diabetes Care. 2002;25:89-94.
[PubMed: 11772907]
445. Timmins P, Donahue S, Meeker J, Marathe P. Steady-state
pharmacokinetics of a novel extended-release metformin formulation.
Clin
Pharmacokinet. 2005;44:721-729.
[PubMed: 15966755]
446. Lebovitz HE. Insulin secretagogues, old and new. Diabetes
Reviews. 1999;7:139-152.
447. Gottschalk M, Danne T, Cara J, Vlajinic A, Izza M. Glimepramide
(GLIM) vs metformin (MET) as monotherapy in pediatric subjects with T2DM:
a single blind comparison study. PediatrDiabetes. 2005;6(suppl
3):24-25 (abstract SP-18).
448. Chiasson J, Josse R, Hunt J, et al. The efficacy of acarbose
in the treatment of patients with non-insulin-dependent diabetes
mellitus. A multicenter controlled clinical trial.
Ann Int
Med. 1994;121:928-935.
[PubMed: 7734015]
449. Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of
troglitazone a in insulin treated patients with type 2 diabetes.
N
Engl J Med. 1998;338:861-866.
[PubMed: 9516220]
450. Law RE, Goetze S, XI X-P, et al. Expression and function
of PPARγ in rat and human vascular smooth muscle
cells.
Circulation. 2000;101:1311-1318.
[PubMed: 10725292]
451. Olefsky JM, Saltiel AR. PPARγ and the
treatment of insulin resistance.
Trends Endocrinol Metab. 2000;11:362-367.
[PubMed: 11042466]
452. Dabiri G, Jones K, Krebs J, et al. Benefits of
rosiglitazone
in children with T2DM (abstract 1904-P). Paper presented at: ADA
Annual Meeting, 2005.
453. Malesker MA.Optimizing antidiabetic treatment options for
patients with type 2 diabetes mellitus and cardiovascular comorbidities. Pharmacotherapy. 2008:28:193-206.
454. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn
T. Once-daily basal insulin glargine versus thrice-daily
prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic
agents (APOLLO): an open randomised controlled trial.
Lancet. 2008;371:1073-1084.
[PubMed: 18374840]
455. Leon DD, Crutchlow MF, Ham JY, Stoffers DA. Role of glucagon-like
peptide-1 in the pathogenesis and treatment of diabetes mellitus.
Int
J Biochem Cell Biol. 2006;38:845-859.
[PubMed: 16202636]
456. Velasquez-Mieyer PA, Cowan PA, Umpierrez GE, Lustig RH,
Cashion AK, Burghen GA. Racial differences in glucagon-like peptide-1 (GLP-1)
concentrations and insulin dynamics during oral glucose tolerance
test in obese subjects.
Int J Obes Relat Metab Disord. 2003;27:1359-1364.
[PubMed: 14574347]
457. Aston-Mourney K, Proietto J, Andrikopoulos S. Investigational
agents that protect pancreatic islet beta-cells from failure.
Expert
Opin Investig Drugs. 2005;14:1241-1250.
[PubMed: 16185166]
458. Summaries for patients. Exenatide or insulin glargine for
suboptimally controlled diabetes? Ann Intern Med. 2005;143:I30.
459. Riddle MC, Drucker DJ. Emerging therapies mimicking the
effects of amylin and glucagon like peptide 1.
Diabetes
Care. 2006;29:435-499.
[PubMed: 16443905]
460. Mari A, Scherbaum WA, Nilsson PM, et al. Characterization
o
the influence of vildagliptin on model-assessed β-cell
function in patients with type 2 diabetes and mild hyperglycemia J
Clin Endocrinol Metab. 2008;93:103-109.
461. Morales A, Rosenbloom AL. Death at the onset of type 2
diabetes (T2D) in African-American youth. Pediatr Res. 2002;51:124A.
462. Hollander AS, Olney RC, Blackett PR, Marshall BA. Fatal
malignant hyperthermia like syndrome with rhabdomyolysis complicating
the presentation of diabetes mellitus in adolescent males.
Pediatrics. 2003;111:1447-1452.
[PubMed: 12777570]
463. Morales A, Rosenbloom AL. Death caused by hyperglycemic
hyperosmolar state at the onset of type 2 diabetes.
J Pediatr. 2004;144:270-273.
[PubMed: 14760275]
464. Fourtner SH, Weinzimer SA, Katz LEL. Hyperglycemic hyperosmolar
nonketotic syndrome in children with type 2 diabetes.
Pediatr
Diabetes. 2005;6:129-135.
[PubMed: 16109068]
465. McDonnell CM, Pedreira CC, Vadamalayan R, Cameron FJ, Werther
GA. Diabetic ketoacidosis, hyperosmolarity and hypernatremia: are
high-carbohydrate drinks worsening initial presentation?
Pediatr
Diabetes. 2005;6:90-94.
[PubMed: 15963036]
466. Kilbane BJ, Mehta S, Backeljauw PF, Shanley TP, Crimmins
NA. Approach to management of malignant hyperthermia-like syndrome
in pediatric diabetes mellitus.
Pediatr Crit Care Med. 2006;7:169-173.
[PubMed: 16531950]
467. Canarie MF, Bogue CW, Banasiak KJ, Weinzimer SA, Tamborlane
WV. Decompensated hyperglycemic hyperosmolarity without significant
ketoacidosis in the adolescent and young adult population.
Pediatr
Diabetes. 2007;20:1115-1124.
[PubMed: 18051930]
468. Azziz R, Ehrmann RS, Legro RS, et al. Troglitazone improves
ovulation and hirsutism in the polycystic ovary syndrome: a multicenter,
double-blind, placebo-controlled trial.
J Clin Endocrinol
Metab. 2001;86:1626-1632.
[PubMed: 11297595]
469. National Heart, Long, and Blood Institute. Report of the
second task force on blood pressure control in children—1987. J
Pediatr. 1987;79:1-25.
470. Haffner SM, Alexander CM, Cook TJ, et al., for the Scandinavian
Simvastatin Survival Study Group. Reduced coronary events in
simvastatin
treated patients with coronary heart disease and diabetes or impaired
fastingglucose levels.
Arch Int Med. 1999;59:2661-2667.
471. Wei JN, Sung FC, Chang CH. Low birth weight and high birth
weight infants are both at an increased risk to have type 2 diabetes
among school children in Taiwan.
Diabetes Care. 2003;26:343-348.
[PubMed: 12547860]
472. Rosenbloom AL, House DV, Winter WE. Non-insulin-dependent
diabetes mellitus (NIDDM) in minority youth: research priorities
and needs.
Clin Pediatr. 1998;37:143-152.
[PubMed: 9492123]